var title_f42_5_43088="Hot liquid balloon ablation 2";
var content_f42_5_43088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hot liquid balloon endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Uterine coverage with Thermachoice uterine balloon endometrial ablation system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Loffer, FD. Gynecare ThermaChoice Uterine Balloon Therapy System: First on the market, long-term results. OBG Management 2005. Copyright &copy; 2005 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43088=[""].join("\n");
var outline_f42_5_43088=null;
var title_f42_5_43089="Patient information: Lice (The Basics)";
var content_f42_5_43089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15487\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/40/2690\">",
"         Types of lice",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/21/34134\">",
"          Pubic lice",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/7/21621\">",
"           Head lice nits",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/44/16065\">",
"         Patient information: Head lice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/12/27843\">",
"         Patient information: Pubic lice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lice (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lice-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H538141982\">",
"      <span class=\"h1\">",
"       What are lice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lice are tiny insects that can live on people&rsquo;s skin and in their hair, and cause itching. Three types of lice can live on or close to people&rsquo;s bodies (",
"      <a class=\"graphic graphic_figure graphicRef67309 \" href=\"mobipreview.htm?2/40/2690\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Head lice",
"        </strong>",
"        can live on your scalp and in the hair on your head",
"       </li>",
"       <li>",
"        <strong>",
"         Body lice",
"        </strong>",
"        can live in the clothes you wear, and feed on your body (these are uncommon)",
"       </li>",
"       <li>",
"        <strong>",
"         Pubic lice,",
"        </strong>",
"        also called &ldquo;crabs,&rdquo; can live in your pubic hair, eyebrows, eyelashes, armpits, beard or mustache, or other areas (",
"        <a class=\"graphic graphic_picture graphicRef64225 \" href=\"mobipreview.htm?33/21/34134\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Lice do not fly or jump. They are spread by person-to-person contact or by sharing clothes and personal items. For example, you can get pubic lice by having sex with someone who has it. You can get head lice by sharing a hat or comb with someone who has it.",
"     </p>",
"     <p>",
"      Lice can lay eggs, also called &ldquo;nits,&rdquo; which then hatch into new lice. People can find lice and nits on their body or in their hair (",
"      <a class=\"graphic graphic_picture graphicRef79421 \" href=\"mobipreview.htm?21/7/21621\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538141989\">",
"      <span class=\"h1\">",
"       How can I tell if I have lice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people have itching on the part of the body where the lice are. With pubic lice, people can also have pale blue spots on the lower belly or upper thighs, or itching and redness of the eyes or eyelids.",
"     </p>",
"     <p>",
"      But some people might not have any symptoms at all. They might find out they have lice only by seeing small white nits or live lice in their hair. Sometimes it is easier to see nits, because lice can move quickly and hide from view.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538141996\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of lice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To get rid of head and pubic lice, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a special fine-toothed comb to carefully comb out nits and lice from your hair",
"       </li>",
"       <li>",
"        Use a non-prescription cream, gel, or lotion on your body or hair that kills lice. Be sure to follow all of the directions on the label.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You may hear or read about other treatments for lice that involve products like olive oil or mayonnaise. Most doctors do not recommend these &ldquo;natural&rdquo; treatments.",
"     </p>",
"     <p>",
"      You will also need to get rid of and kill the lice on items in your home so you don&rsquo;t get lice again. To do this, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash clothes, bedding, and towels in hot water and dry them on the hottest setting",
"       </li>",
"       <li>",
"        Vacuum your carpets and furniture",
"       </li>",
"       <li>",
"        Put things you cannot wash into a sealed plastic bag for 2 weeks",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you or your child has lice:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        All of the adults and children in the home should be checked for lice",
"       </li>",
"       <li>",
"        Talk with the school nurse about when your child can return to school",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have pubic lice, you need to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tell anyone you had sex with in the past month, so he or she can be treated, too",
"       </li>",
"       <li>",
"        Be tested for other diseases you can catch when you have sex. The person who gave you pubic lice might have given you another disease, too.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538142003\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you can&rsquo;t get rid of your lice by doing the things described above, see your doctor or nurse. He or she might prescribe a stronger lotion or a pill for you to take.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538142010\">",
"      <span class=\"h1\">",
"       What can I do to prevent getting lice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting lice by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not sharing a bed, clothes or personal items with someone who has lice",
"       </li>",
"       <li>",
"        Not having sex with someone who has pubic lice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538142017\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/44/16065?source=see_link\">",
"       Patient information: Head lice (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/12/27843?source=see_link\">",
"       Patient information: Pubic lice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/5/43089?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15487 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43089=[""].join("\n");
var outline_f42_5_43089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538141982\">",
"      What are lice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538141989\">",
"      How can I tell if I have lice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538141996\">",
"      Is there anything I can do on my own to get rid of lice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538142003\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538142010\">",
"      What can I do to prevent getting lice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538142017\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/40/2690\">",
"      Types of lice",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/21/34134\">",
"       Pubic lice",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/7/21621\">",
"        Head lice nits",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/44/16065?source=related_link\">",
"      Patient information: Head lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/12/27843?source=related_link\">",
"      Patient information: Pubic lice (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43090="Tumor embolus Gross";
var content_f42_5_43090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary tumor embolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autopsy photograph shows a serpiginous tumor embolus at the bifurcation of the pulmonary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43090=[""].join("\n");
var outline_f42_5_43090=null;
var title_f42_5_43091="Patient consent form - page 1";
var content_f42_5_43091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Patient consent form - page 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 721px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43091=[""].join("\n");
var outline_f42_5_43091=null;
var title_f42_5_43092="Dactinomycin: Patient drug information";
var content_f42_5_43092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dactinomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     see \"Dactinomycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/61/8150?source=see_link\">",
"     see \"Dactinomycin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cosmegen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep away from your skin, nose, and eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dactinomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11201 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43092=[""].join("\n");
var outline_f42_5_43092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031505\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031507\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031506\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031511\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031512\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031514\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031509\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031516\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=related_link\">",
"      Dactinomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/61/8150?source=related_link\">",
"      Dactinomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43093="Occiput anterior position";
var content_f42_5_43093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63528%7EOBGYN%2F73262%7EOBGYN%2F52247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63528%7EOBGYN%2F73262%7EOBGYN%2F52247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Occiput anterior positions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 159px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: Right occiput anterior (ROA); B: Left occiput anterior (LOA); C: Occiput anterior (OA).",
"     <br>",
"      * Posterior fontanel. This is the smaller of the two fontanels and is at the intersection of the three sutures: the sagittal suture and two lambdoid sutures.",
"      <br>",
"       ** Anterior fontanel. This large fontanel is at the intersection of four sutures: the sagittal, frontal, and two coronal sutures.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occiput posterior position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Occiput transverse positions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Right occiput transverse (ROT), (B) Left occiput transverse (LOT).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43093=[""].join("\n");
var outline_f42_5_43093=null;
var title_f42_5_43094="Informed consent";
var content_f42_5_43094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Informed consent",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Marsha Ryan, MD, JD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Michael S Sinha, MD, JD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43094/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/5/43094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16860339\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians have a legal and ethical responsibility to provide adequate information to the patient so that he or she is able to process the information and make appropriate decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/1\">",
"     1",
"    </a>",
"    ]. An educated patient also benefits the physician, both in terms of cooperation in the planned intervention and in reducing acrimony in case of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/1\">",
"     1",
"    </a>",
"    ]. The physician who teaches and responds carefully brings the patient into the medical decision making process, addresses the patient&rsquo;s concerns, and creates reasonable expectations regarding outcomes.",
"   </p>",
"   <p>",
"    This topic focuses on the informed consent session. Additional information regarding the consent process and related ethical issues for adolescent health care, gynecologic care, the intensive care unit, and end of life care is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Informed consent and patient expectations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=see_link\">",
"     \"Legal aspects of end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3317023\">",
"    <span class=\"h1\">",
"     BENEFITS OF INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of obtaining informed consent extend beyond the simple transmission of information from someone who has knowledge (the physician) to someone who does not (the patient). The benefits of truly informed consent include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Engaging the patient in his or her health care",
"     </li>",
"     <li>",
"      Enhancing the physician-patient relationship",
"     </li>",
"     <li>",
"      Encouraging physicians to thoroughly review the patient&rsquo;s therapeutic options",
"     </li>",
"     <li>",
"      Reducing discontent and litigation when there are complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315262\">",
"    <span class=\"h1\">",
"     INFORMED DECISION MAKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;No intervention can be undertaken without the patient&rsquo;s consent, which must be voluntary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/2\">",
"     2",
"    </a>",
"    ]. In order for consent to be valid, the patient must be competent. In the setting of informed consent, competence or capacity means that the patient has the mental ability to understand problems and make decisions about accepting or rejecting medical treatments that are offered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Competence is always presumed unless there are obvious clinical (eg, severe mental illness) or judicial (eg, a determination of incompetence at a competency hearing) reasons to doubt competency.",
"     </li>",
"     <li>",
"      In instances of temporarily diminished capacity, a physician is obligated to reassess capacity to consent over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/3\">",
"       3",
"      </a>",
"      ]. If a patient is deemed incompetent by a court of law, the duty of informed consent extends to the patient&rsquo;s proxy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to meet the requirements for effective, informed decision making, a physician must disclose material facts as well as appropriate additional disclosures. These are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315269\">",
"    <span class=\"h2\">",
"     Material facts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Material facts are those that are relevant to decision making and usually include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis. The method and alternative means of diagnosis may be relevant, particularly when invasive diagnostic techniques are utilized.",
"     </li>",
"     <li>",
"      Proposed treatment.",
"     </li>",
"     <li>",
"      Risks and benefits of treatment.",
"     </li>",
"     <li>",
"      Alternative treatment options (surgical or medical) along with their risks and benefits.",
"     </li>",
"     <li>",
"      The risks of refusing treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Material facts include information about events that occur frequently, even if these complications would be considered minor, such as a superficial wound infection or a hematoma. Material facts also include rare events that represent major complications (eg, death, loss of mobility, loss of reproductive function or continence, or the need for a stoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physician must decide what facts about a procedure should be presented and how detailed the discussion with a patient should be. There are no hard and fast rules about percentages of risk or degrees of harm that require discussion. In addition, the standards may vary from one patient or jurisdiction to another. For instance, in Texas, state regulations delineate specific risks or hazards associated with certain procedures that must be disclosed in each instance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3316516\">",
"    <span class=\"h2\">",
"     Physician disclosure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physician must answer truthfully if a patient asks questions about the number of similar procedures performed and their success rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Failure to answer honestly may leave a physician open to claims of fraud and misrepresentation, as well as negligent nondisclosure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The law mandates disclosure of a physician&rsquo;s financial conflict(s) of interest, since the law presumes that there is the potential for undue influence on that physician&rsquo;s medical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/11\">",
"     11",
"    </a>",
"    ]. Examples include referral to a laboratory, an ambulatory surgery center, or a radiology service in which the physician has ownership. Patients must be given the opportunity to seek care in an independent facility. There may also be disclosure requirements if the physician has a commercial interest in the use of a patient&rsquo;s cells or in the use of new devices or techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are not entitled to know everything about a provider&rsquo;s personal attributes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/13\">",
"     13",
"    </a>",
"    ]. However, some courts have mandated disclosure of a physician&rsquo;s own alcohol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/14\">",
"     14",
"    </a>",
"    ] and HIV status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Other courts refuse to mandate voluntary disclosure, concluding that those physician-specific facts are not material, and that it is an unwarranted invasion of the physician&rsquo;s privacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/13,17\">",
"     13,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19730393\">",
"    <span class=\"h2\">",
"     Personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physician must advise patients of all personnel and their respective roles, including residents, students, and equipment representatives. It is particularly important for patients to know who will be performing what segments of a procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/18\">",
"     18",
"    </a>",
"    ]. Some patients object to having part or all of their procedure or operation done by others than the physician they originally chose. Patients retain the right to refuse participation by residents and students. Physicians also have the right to refuse to take care of patients who will not allow residents to participate in procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3316932\">",
"    <span class=\"h2\">",
"     Additional procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is prudent for the physician to inform patients of any additional procedures that may be necessary for a successful outcome or that are recommended to prevent future health problems. Examples might include en bloc resection of adjacent structures in a cancer operation or a protective colostomy or ileostomy for a low anterior anastomosis. In such cases, preoperative discussion about the stoma, preoperative marking for a potential stoma site, and counseling with the stomal therapist may help the patient prepare for the procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315520\">",
"    <span class=\"h1\">",
"     EFFECTIVE COMMUNICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physician can maximize the effectiveness of an informed consent session by communicating in terms patients and their families can understand. Important elements of effective communication are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315527\">",
"    <span class=\"h2\">",
"     Focus on the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The legal principles of informed consent promote patient autonomy, the notion that patients should decide who touches them and how that contact is made. Thus, the physician should be wary of too much pressure, too little information, or too little attention to the patient&rsquo;s need for information, understanding, and comfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/1\">",
"     1",
"    </a>",
"    ]. As Supreme Court Justice Benjamin Cardozo once wrote, &ldquo;Every human being of adult years and sound mind has a right to determine what shall be done with his body&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians must focus on the patient&rsquo;s understanding and consent. Including relatives in the discussion may be good practice when patients allow them to join the conversation, but decisions made by family members can never countermand that of a competent adult patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19831?source=see_link\">",
"     \"A patient-centered view of the clinician-patient relationship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3316955\">",
"    <span class=\"h2\">",
"     Comprehensible language",
"    </span>",
"    &nbsp;&mdash;&nbsp;The language used to obtain consent must be comprehensible to the patient and cannot be a simple list. In order to protect themselves from such uncertainty, some physicians give patients exhaustive lists of every conceivable thing that might go wrong. However, the transmission of important information requires more than an impersonal, boiler-plate listing of minutiae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/5\">",
"     5",
"    </a>",
"    ]. Rather, personal transmission of truly relevant data should be accomplished. The physician should present the information that someone in the patient&rsquo;s situation needs to know in order to make a truly educated decision. (&ldquo;If I were in this patient&rsquo;s shoes, what would I want to know?&rdquo;). (See",
"    <a class=\"local\" href=\"#H3315269\">",
"     'Material facts'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315534\">",
"    <span class=\"h3\">",
"     Educational material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Literature or other teaching tools that are targeted to lay readers, such as patient pamphlets or videos, can improve communication and patient understanding of planned procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17609?source=see_link\">",
"     \"Literacy and patient care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315541\">",
"    <span class=\"h3\">",
"     Interpreters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpreters are necessary for non-English speakers and a translator skilled in medical terminology is ideal for the purpose of transmitting accurate information. Translation should not be left to family members, as they may withhold information from a patient in order to protect him or her from hearing bad news. In such cases, incomplete or misleading information may be all the patient receives, and the physician will not realize that information was not effectively or completely communicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Joint Commission defines health literacy as &ldquo;the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/23\">",
"     23",
"    </a>",
"    ]. The educational, social, and cultural factors that influence the expectations and preferences of the individual must also be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, if additional clarification and explanation is needed, the conversation must be expanded, and it must be tailored to the individual needs of the patient. In the end, the patient has to hear, understand, and agree to the proposed procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24537?source=see_link\">",
"     \"Cross-cultural care and communication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315548\">",
"    <span class=\"h2\">",
"     Emergency situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In emergency situations or when the patient is sick or in pain, the patient may be less capable of receiving, interpreting, or communicating information. The medical facts must be explained carefully and deliberately to the patient and to family members or others invited into the discussion by the patient, as the urgency of the situation allows.",
"   </p>",
"   <p>",
"    In some cases, the need for consent may be outweighed by the need for urgent intervention and the physician proceeds as expeditiously as the situation requires [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/25\">",
"     25",
"    </a>",
"    ]. If at all possible, family members should be contacted if they are not present. When available, living wills and durable powers of attorney should be consulted.",
"   </p>",
"   <p>",
"    The duty of informed consent extends to a patient&rsquo;s proxy or surrogate decision maker. If a patient regains capacity, the duty of informed consent returns to the patient and the role of the proxy in informed decision making is extinguished. This is why reassessment of the patient&rsquo;s capacity is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315555\">",
"    <span class=\"h2\">",
"     Comatose or incompetent patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incompetent patients are patients who lack adequate decision making capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/26\">",
"     26",
"    </a>",
"    ]. Physicians must assess all such patients for capacity regardless of their current (or presumed) incompetence. It may be necessary to seek psychiatric consultation if there is doubt about the patient&rsquo;s capacity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=see_link&amp;anchor=H9#H9\">",
"     \"Ethics in the intensive care unit: Informed consent\", section on 'Incapacitated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following guidelines regarding competency should be followed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      So long as the patient remains competent, his or her expressed wishes supersede any document or the wishes of any surrogate.",
"     </li>",
"     <li>",
"      When patients are comatose or otherwise incompetent, living wills may dictate some elements of care, and durable powers of attorney will name surrogate decision makers who can direct care.",
"     </li>",
"     <li>",
"      A transiently incapacitated patient may regain capacity, especially when emerging from the influence of alcohol, drugs, or hospital-administered analgesics or sedatives. Such patients should not be deemed incompetent by default and must be assessed, and reassessed as necessary, for capacity before healthcare decisions are made, particularly those that are not emergent.",
"     </li>",
"     <li>",
"      A patient&rsquo;s status as involuntarily committed for mental illness does not eliminate the need for informed consent nor does it necessarily prevent that patient from being able to consent to, or to refuse, surgical intervention or other invasive procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3315562\">",
"    <span class=\"h1\">",
"     DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may not accurately remember all the facts disclosed in a discussion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Thus, a physician must document the content of informed consent sessions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The informed consent discussion and its documentation should be done by the physician who will be performing the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Delegating the responsibility to obtain consent to someone else does",
"      <strong>",
"       not",
"      </strong>",
"      absolve the physician of liability if that consent session is incomplete or ineffective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The physician should date and time the written summary of what was said and to whom, making note of relatives, friends, or support staff such as nurses or interpreters who are present. All elements of the discussion should be reduced to writing: diagnosis, proposed treatment with its risks and benefits, and alternative treatments with their risks and benefits.",
"     </li>",
"     <li>",
"      It is not sufficient to state that &ldquo;the risks and benefits were discussed&rdquo; without further description of the specifics. The physician should document that the patient understood the concepts as discussed, and agreed to proceed. In addition, the physician should document that the patient was provided with appropriate literature, the patient had the opportunity to ask questions, and that those questions were answered. The standard consent document means little, particularly in its generic form. The real work of obtaining informed consent is documented in office or hospital notes.",
"     </li>",
"     <li>",
"      Documentation is particularly important when patients refuse intervention. The physician must note in the record the specific risks associated with delay or refusal which were disclosed.",
"     </li>",
"     <li>",
"      When informed consent cannot be obtained due to an emergency situation or diminished capacity due to intoxication, trauma, or disease, physicians must document in the written record what facts were considered in determining the patient&rsquo;s ability to process information and make reasonable decisions.",
"     </li>",
"     <li>",
"      When capacity must be reassessed, further documentation is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8537345\">",
"    <span class=\"h1\">",
"     FAILURE TO OBTAIN CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to provide the necessary, relevant information in a manner that truly communicates with the patient may constitute ineffective, and therefore nonexistent, consent. There are two legal theories of recovery for failure to obtain informed consent: battery action and negligent nondisclosure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8537352\">",
"    <span class=\"h2\">",
"     Battery action",
"    </span>",
"    &nbsp;&mdash;&nbsp;A battery action is an action for a &ldquo;touching&rdquo; to which the patient did not agree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/18,33\">",
"     18,33",
"    </a>",
"    ]. In some jurisdictions, inadequate disclosure of risks adds up to no consent at all, and thus a claim of battery may be made, even if the procedure is technically successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/34\">",
"     34",
"    </a>",
"    ]. The rationale in such cases is that a poorly informed patient cannot legally consent in any meaningful way, and thus any nominal agreement is void [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Battery actions are infrequent in the medical arena and, in most jurisdictions, the typical case in which a plaintiff asserts an absence of informed consent is termed &ldquo;negligent nondisclosure&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/35\">",
"     35",
"    </a>",
"    ]. Usually, the patient says he or she did sign the consent form, but was not thoroughly and comprehensibly made aware of the nature of the proposed procedure and its risks. This claim is sometimes made by itself, but is more commonly appended to the standard medical malpractice claim that the physician did not perform the procedure according to industry standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8537359\">",
"    <span class=\"h2\">",
"     Negligent nondisclosure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negligent nondisclosure cases are typical negligence cases, and as such, there are four elements that must be shown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duty &ndash; The duty is the requirement that a physician act as a minimally competent, similarly trained, reasonable physician in similar circumstances would act when disclosing information.",
"     </li>",
"     <li>",
"      Breach of duty &ndash; Breach of duty is failure to meet the minimal standard of care.",
"     </li>",
"     <li>",
"      Injury &ndash; The injury is the harm that befalls the patient.",
"     </li>",
"     <li>",
"      A causal relationship &ndash; A causal relationship between the breach and the harm is shown when the patient reasonably declares that he would have refused to undergo the procedure had he known the true nature of the risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If all four elements are proven to the jury, the physician is liable for the tort of negligent nondisclosure. Typically, the proof of all four elements lies in the testimony of the plaintiff&rsquo;s expert witness, who must present the following information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Define the duty &ndash; The details that constitute an appropriate informed consent discussion are defined.",
"     </li>",
"     <li>",
"      Identify the breach &ndash; The details that were wrongly omitted are defined.",
"     </li>",
"     <li>",
"      Clarify the harm &ndash; The injuries that were suffered are defined.",
"     </li>",
"     <li>",
"      Identify alternatives &ndash; The alternatives that a reasonable patient might have selected instead are defined. These may include a different procedure, a different physician, or a different facility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The plaintiff then adds that he or she, being a reasonable patient, would have refused to consent to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16860353\">",
"    <span class=\"h1\">",
"     THE DUTY TO INFORM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general ways in which jurisdictions may judge the physician&rsquo;s performance of his or her duty to inform: the professional standard, the objective patient standard, and the subjective standard. However, each state handles negligent nondisclosure cases differently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16860360\">",
"    <span class=\"h2\">",
"     Professional standard",
"    </span>",
"    &nbsp;&mdash;&nbsp;The professional standard of care requires that a physician must disclose those facts that a reasonable physician who was faced with this particular set of circumstances would disclose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, the standard is set by the profession, and the individual physician must adhere to accepted medical standards, as defined by the defendant&rsquo;s expert witness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8056860\">",
"    <span class=\"h2\">",
"     Patient-centered standards",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the requirement for expert witnesses in jurisdictions in which the professional standard is applied, there is generally no need for an expert in the patient-centered jurisdictions. An expert may be helpful in presenting the scientific facts about procedures and risks. However, a lay jury is deemed capable of deciding what an ordinary patient would consider relevant in order to consent to a surgical procedure. There are both objective and subjective patient-centered standards:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Objective",
"      </strong>",
"      &ndash; The objective standard of care requires that the physician determine what a reasonable patient would find indispensible when evaluating his or her options and then include these issues in the informed consent dialogue. For elective, cosmetic, or high risk procedures, the physician&rsquo;s burden of disclosure is even higher, because a reasonable patient might be more likely to decline the proposed procedure or choose another therapeutic option. The patient must show that, had he or she known the necessary and pertinent facts, he or she would have refused to proceed. Thus, the physician must disclose those facts that a reasonable patient in a similar situation would need to know in order to make an informed choice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Subjective",
"      </strong>",
"      &ndash; The subjective standard for disclosure requires the physician to relay facts that a particular patient deems important in the decision making process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/40\">",
"       40",
"      </a>",
"      ]. Proponents assert that the right to self-determination requires that a patient be able to decline a particular treatment even if a reasonable person would consent, and only a subjective standard can fully protect that right [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/41\">",
"       41",
"      </a>",
"      ]. The subjective standard promotes the greatest patient autonomy as compared to the professional standard or objective standard. However, it is difficult for physicians to know what facts are relevant to an individual patient&rsquo;s decision making and defend against hindsight. As an example, an injured patient may state that he or she would not have consented to a procedure with the possibility of a particular poor outcome that was not disclosed during the informed consent dialogue. The patient need only declare his or her own particular belief that he would have refused, and the jury must then simply decide whether or not the patient&rsquo;s claim is credible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43094/abstract/5\">",
"       5",
"      </a>",
"      ]. This standard is seldom used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16860423\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physician has a legal and ethical responsibility to provide adequate information to the patient so that he or she is able to process the information and make appropriate decisions. (See",
"      <a class=\"local\" href=\"#H16860339\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No procedure can be undertaken without the patient&rsquo;s agreement. The patient&rsquo;s consent must be voluntary and competent. (See",
"      <a class=\"local\" href=\"#H3315262\">",
"       'Informed decision making'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to meet the requirements for effective, informed decision making, a physician must disclose material facts, which are relevant to decision making, including the patient&rsquo;s diagnosis, proposed treatment, risks and benefits of the treatment, alternative treatments along with their risks and benefits, and the risks of refusal. (See",
"      <a class=\"local\" href=\"#H3315269\">",
"       'Material facts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A physician must answer truthfully about the number of similar procedures or cases performed, and disclose success rates, and any financial conflict(s) of interest. (See",
"      <a class=\"local\" href=\"#H3316516\">",
"       'Physician disclosure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physician must advise patients of all personnel involved in their care and their respective roles, including residents, students, and equipment representatives. (See",
"      <a class=\"local\" href=\"#H19730393\">",
"       'Personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is prudent for the physician to inform patients of any additional procedures that may be necessary for a successful outcome. (See",
"      <a class=\"local\" href=\"#H3316932\">",
"       'Additional procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physician can maximize the effectiveness of an informed consent session by communicating in terms patients and their families can understand. Important elements of effective communication include focusing on the patient, using comprehensible language, offering educational material, and using interpreters when necessary. (See",
"      <a class=\"local\" href=\"#H3315520\">",
"       'Effective communication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may not accurately remember all of the facts disclosed in teaching sessions. Thus, the physician must document the content of informed consent sessions. (See",
"      <a class=\"local\" href=\"#H3315562\">",
"       'Documentation'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Failure to provide the necessary, relevant information in a way which truly communicates with the patient may constitute ineffective, and therefore nonexistent, consent. (See",
"      <a class=\"local\" href=\"#H8537345\">",
"       'Failure to obtain consent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Berg JW, Appelbaum PS, Lidz CW, et al. Informed Consent: Legal Theory and Clinical Practice, 2nd edition, Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/2\">",
"      Benak LD, Applegate S. Informed consent and issues surrounding lack of capacity vs. incompetence. J Forensic Nurs 2006; 2:48, 45.",
"     </a>",
"    </li>",
"    <li>",
"     Black's Law Dictionary, 9th ed, Garner BA.  (Ed), West Group, St. Paul, MN 2009.",
"    </li>",
"    <li>",
"     Canterbury v. Spence, 464 F.2d 772, 782 (C.A.D.C. 1972).",
"    </li>",
"    <li>",
"     Cobbs v. Grant, 502 P.2d 1, 12 (Cal. 1972).",
"    </li>",
"    <li>",
"     See 25 Tex. Admin. Code &sect; 601.2 (2011).",
"    </li>",
"    <li>",
"     Johnson v. Kokemoor 545 N.W.2d 495 (Wis. 1996).",
"    </li>",
"    <li>",
"     Hales v. Pittman, 576 P.2d 493 (1978).",
"    </li>",
"    <li>",
"     Duttry v. Patterson, 771 A.2d 1255 (Pa. 2001).",
"    </li>",
"    <li>",
"     Howard v. Univ. of Med. &amp; Dentistry of N.J., 800 A.2d 73,83 (N.J. 2002).",
"    </li>",
"    <li>",
"     See, eg, Tennessee Code &sect; 63-6-502 (2009).",
"    </li>",
"    <li>",
"     Moore v. Regents of the University of California, 793 P.2d 479, 483 (Cal 1990).",
"    </li>",
"    <li>",
"     Albany Urology Clinic, P.C. v. Cleveland, 528 S.E.2d 777, 782 at n.19 (Ga., 2000).",
"    </li>",
"    <li>",
"     Hidding v. Williams, 578 So.2d 1192 (La.App. 5 Cir., 1991).",
"    </li>",
"    <li>",
"     Doe v. Noe, 690 N.E.2d 1012 (Ill.App. 1 Dist., 1997).",
"    </li>",
"    <li>",
"     Faya v. Almaraz, 620 A.2d 327 (Md. 1993).",
"    </li>",
"    <li>",
"     Mau v. Wisconsin Patients Compensation Fund, 668 N.W.2d 562 (Wis.App., 2003).",
"    </li>",
"    <li>",
"     Murphy v. Implicito, 920 A.2d 678 (N.J.Super.App., 2007).",
"    </li>",
"    <li>",
"     Schloendorff v. Society of New York Hospital, 211 N.Y. 125, 129 (1914).",
"    </li>",
"    <li>",
"     Nishi v. Hartwell, 473 P.2d 116 (Hawaii, 1970).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/21\">",
"      Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res 2007; 42:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/22\">",
"      Schenker Y, Wang F, Selig SJ, et al. The impact of language barriers on documentation of informed consent at a hospital with on-site interpreter services. J Gen Intern Med 2007; 22 Suppl 2:294.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Commission \"What Did the Doctor Say?\": Improving Health Literacy to Protect Patient Safety, Executive Summary file://www.jointcommission.org/assets/1/18/improving_health_literacy.pdf (Accessed on April 12, 2011).",
"    </li>",
"    <li>",
"     Institute of Medicine report. Health Literacy: A Prescription to End Confusion, National Academies Press, 2004.",
"    </li>",
"    <li>",
"     Dewes v. Indian Health Service, 504 F.Supp 203 (D. S.D. 1980).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/26\">",
"      Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. N Engl J Med 2007; 357:1834.",
"     </a>",
"    </li>",
"    <li>",
"     Hanes v. Ambrose, 80 A.D.2d 963 (3d Dep&rsquo;t 1981).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/28\">",
"      Robinson G, Merav A. Informed consent: recall by patients tested postoperatively. Ann Thorac Surg 1976; 22:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43094/abstract/29\">",
"      Herz DA, Looman JE, Lewis SK. Informed consent: is it a myth? Neurosurgery 1992; 30:453.",
"     </a>",
"    </li>",
"    <li>",
"     See Jamison v. Kilgore, 905 So. 2d 610 (Miss. Ct. App. 2004)",
"    </li>",
"    <li>",
"     Panea v. Isdaner, 773 A.2d 782 (2001).",
"    </li>",
"    <li>",
"     Goss v. Oklahoma Blood Institute, 856 P.2d 998 (1990).",
"    </li>",
"    <li>",
"     Morvillo v. Shenandoah Memorial Hosp., 547 F.Supp.2d 528 (W.D.Va. 2008).",
"    </li>",
"    <li>",
"     Shetter v. Rochelle, 409 P.2d 74, 82 (1965).",
"    </li>",
"    <li>",
"     Paden v. Rudd, 669 S.E.2d 548 (Ga.App.,2008).",
"    </li>",
"    <li>",
"     Ey RM. \"Cause of Action Against Physician for Failure to Obtain Patient's Informed Consent,\" 5 Causes Of Action &sect; 1 (Updated September 2010).",
"    </li>",
"    <li>",
"     Miller-McGee v. Washington Hosp. Center, 920 A.2d 430, 440 (D.C. 2007).",
"    </li>",
"    <li>",
"     Aiken v. Clary, 396 S.W.2d 668 (Mo. 1965).",
"    </li>",
"    <li>",
"     Canterbury v. Spence, 464 F.2d 772, 791 (1972).",
"    </li>",
"    <li>",
"     Bloskas v. Murray, 646 P.2d 907 (Colo. 1982).",
"    </li>",
"    <li>",
"     Scott v. Bradford, 606 P.2d 554,559 (Okl. 1980).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15076 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43094=[""].join("\n");
var outline_f42_5_43094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16860423\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16860339\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3317023\">",
"      BENEFITS OF INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3315262\">",
"      INFORMED DECISION MAKING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3315269\">",
"      Material facts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3316516\">",
"      Physician disclosure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19730393\">",
"      Personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3316932\">",
"      Additional procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3315520\">",
"      EFFECTIVE COMMUNICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3315527\">",
"      Focus on the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3316955\">",
"      Comprehensible language",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3315534\">",
"      - Educational material",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3315541\">",
"      - Interpreters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3315548\">",
"      Emergency situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3315555\">",
"      Comatose or incompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3315562\">",
"      DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8537345\">",
"      FAILURE TO OBTAIN CONSENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8537352\">",
"      Battery action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8537359\">",
"      Negligent nondisclosure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16860353\">",
"      THE DUTY TO INFORM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16860360\">",
"      Professional standard",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8056860\">",
"      Patient-centered standards",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16860423\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19831?source=related_link\">",
"      A patient-centered view of the clinician-patient relationship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24537?source=related_link\">",
"      Cross-cultural care and communication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17609?source=related_link\">",
"      Literacy and patient care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43095="Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults";
var content_f42_5_43095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43095/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/5/43095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scleroderma spectrum disorders can be subdivided into three groups: systemic sclerosis, localized scleroderma, and scleroderma-like conditions, comprising a heterogeneous group of diseases linked by the presence of thickened, sclerotic skin. The extracutaneous manifestations of these conditions are quite diverse, and differences between systemic sclerosis and its mimickers have required the development of a classification system that takes into account the different potential complications, prognoses, and management strategies for patients with these disorders. The classification of scleroderma spectrum disorders is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic sclerosis has an annual incidence of 1 to 2 per 100,000 individuals in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/1\">",
"     1",
"    </a>",
"    ]. The peak onset is between the ages of 30 and 50, and the disease is more common in women. The diagnosis of systemic sclerosis and related disorders is based primarily upon the presence of characteristic clinical findings. The various cutaneous and visceral manifestations of systemic sclerosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic sclerosis has two distinct subsets: diffuse cutaneous systemic sclerosis (DcSSc) and limited cutaneous systemic sclerosis (LcSSc). These subsets of systemic sclerosis are defined on the basis of the extent of skin involvement. Patients with LcSSc may display features of the CREST syndrome (",
"    <strong>",
"     c",
"    </strong>",
"    alcinosis cutis,",
"    <strong>",
"     R",
"    </strong>",
"    aynaud phenomenon,",
"    <strong>",
"     e",
"    </strong>",
"    sophageal dysmotility,",
"    <strong>",
"     s",
"    </strong>",
"    clerodactyly, and",
"    <strong>",
"     t",
"    </strong>",
"    elangiectasia).",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and differential diagnosis of systemic sclerosis in adults. Localized scleroderma, scleroderma-like conditions, and scleroderma disorders in childhood are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF SYSTEMIC SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of systemic sclerosis is suggested by the presence of skin thickening and hardening (sclerosis) that is not confined to one area (ie, not localized scleroderma). The diagnosis is supported by the presence of extracutaneous features and characteristic serum autoantibodies.",
"   </p>",
"   <p>",
"    A skin biopsy is generally not essential for confirmation of the diagnosis. However, in some cases, a skin biopsy may be necessary to help differentiate systemic sclerosis from other syndromes such as eosinophilic fasciitis, scleredema, or scleromyxedema. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Attention must be paid to the nuances of particular features of skin involvement. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extent of skin induration varies from patient to patient. Almost all patients have skin involvement in the fingers (sclerodactyly), hands, and face.",
"     </li>",
"     <li>",
"      During the first few months of disease, it may be difficult to make a firm diagnosis of systemic sclerosis. At this \"inflammatory stage\" of the disease, arthralgia and soft tissue swelling rather than skin induration may be the most prominent features, suggesting rheumatoid arthritis or another connective tissue disease.",
"     </li>",
"     <li>",
"      The presence of calcinosis cutis, hyperpigmentation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cutaneous telangiectasia may be helpful in confirming the diagnosis but are variable and often absent in early disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evidence of extracutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a thorough physical examination, investigation targeting specific organ involvement and testing for certain serum autoantibodies are useful for confirmation of the diagnosis and for accurate classification. As an example, the diagnosis of systemic sclerosis in a person suffering from Raynaud phenomenon is supported by the presence of heartburn or by dysphagia and evidence of disordered esophageal motility on manometric testing. Esophageal dysmotility is the most frequent visceral complication of systemic sclerosis but is not seen in patients with primary Raynaud phenomenon. The demonstration of microvascular changes on nailfold capillaroscopy also points toward systemic sclerosis in this setting (",
"    <a class=\"graphic graphic_picture graphicRef72422 \" href=\"mobipreview.htm?0/38/608\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The combination of skin induration plus the presence of one or more of the following clinical features supports the diagnosis of systemic sclerosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heartburn",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysphagia of new onset",
"     </li>",
"     <li>",
"      Acute onset of hypertension and renal insufficiency",
"     </li>",
"     <li>",
"      Dyspnea on exertion associated with interstitial pulmonary changes on radiography",
"     </li>",
"     <li>",
"      Pulmonary hypertension",
"     </li>",
"     <li>",
"      Diarrhea with malabsorption",
"     </li>",
"     <li>",
"      Characteristic mucocutaneous telangiectasia on the face, lips, oral cavity, or hands",
"     </li>",
"     <li>",
"      Digital infarctions and or digital tip pitting",
"     </li>",
"     <li>",
"      Erectile dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are helpful in confirming but not in excluding a diagnosis of systemic sclerosis (SSc). Antinuclear antibody (ANA) screening and specific tests for antitopoisomerase I (anti-Scl-70), anticentromere (ACA), anti-RNA polymerase III, and anti-beta2-glycoprotein I antibodies are suggested for patients suspected of having SSc. The antitopoisomerase I, ACA, and anti-RNA polymerase III tests are highly specific (&gt;99.5 percent in some studies) for SSc but are only moderately sensitive (20 to 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The autoantibodies are almost always mutually exclusive. Each may also have prognostic implications (see below).",
"   </p>",
"   <p>",
"    A number of other autoantibodies may be present in patients with SSc; over 95 percent of SSc patients have at least one autoantibody. Routine testing for other autoantibodies is not usually necessary. Immunofluorescence for some of these reveals a nucleolar staining pattern (",
"    <a class=\"graphic graphic_picture graphicRef53431 \" href=\"mobipreview.htm?42/13/43224\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ACA, antitopoisomerase I, and other autoantibodies in systemic sclerosis are associated with specific clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef59732 \" href=\"mobipreview.htm?10/18/10541\">",
"     table 1",
"    </a>",
"    ). In one study, the type of specific autoantibody in an individual patient was a better predictor of clinical manifestations than classification into dSSc and lSSc subsets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/5\">",
"     5",
"    </a>",
"    ]. The following general statements apply to SSc-associated autoantibodies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of anticentromere antibodies (ACA) is usually associated with limited cutaneous systemic sclerosis (LcSSc); only 5 percent of patients with diffuse cutaneous SSc have ACA.",
"     </li>",
"     <li>",
"      Anti-DNA topoisomerase I (Scl-70) antibodies are associated with diffuse cutaneous SSc (DcSSc) and a higher risk of severe interstitial lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/2,6\">",
"       2,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to U3-RNP (fibrillarin) are associated with an increased risk for SSc-associated pulmonary hypertension (PAH) and skeletal muscle involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-PM-Scl autoantibodies are associated with myositis in patients with systemic sclerosis. Approximately one-quarter of patients with a systemic",
"      <span class=\"nowrap\">",
"       sclerosis/myositis",
"      </span>",
"      overlap have antibodies to components of this nucleolus-derived antigen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-beta2-glycoprotein I (&szlig;2GPI) antibodies, which are associated with recurrent thromboembolic events in patients with the antiphospholipid antibody syndrome, are also associated with macrovascular disease in SSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/10\">",
"       10",
"      </a>",
"      ]. Both anticardiolipin and anti-beta2GPI antibodies can be seen in SSc. Anti-&szlig;2GPI antibodies, particularly the IgA isotype, were associated with increased risk of ischemic digital loss, active digital ischemia, and echocardiographic evidence for PAH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of high titers of rheumatoid factor, antibodies to citrullinated peptides (anti-CCP), anti-U1-RNP antibodies, or lupus-associated antibodies (eg, anti-double stranded DNA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-Smith) is uncommon in patients with SSc and points toward overlap syndromes with other connective tissue diseases. These syndromes are characterized by a more prominent arthritis than seen in systemic sclerosis alone and may be associated with features of SLE. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"       \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies to RNA polymerase III are found in patients with DcSSc and are associated with increased risk for scleroderma renal crisis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to RNA polymerase II are also found in patients with either systemic sclerosis or systemic lupus erythematosus (SLE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of SSc-associated antibodies (antitopoisomerase-I, anticentromere, anti-RNA polymerase III, or",
"      <span class=\"nowrap\">",
"       anti-Th/To),",
"      </span>",
"      in patients with Raynaud phenomenon but without definite SSc or a related autoimmune rheumatic disease, predicts an increased risk of progression to SSc, particularly in combination with abnormal nailfold capillaroscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\", section on 'Secondary Raynaud phenomenon'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antineutrophil cytoplasmic antibodies (ANCA) are often ordered indiscriminately in patients with suspected connective tissue disease but are not associated with systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One report found antimyeloperoxidase P-ANCA in 2 of 81 patients with systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/15\">",
"     15",
"    </a>",
"    ]. The antibodies appeared after therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    in one patient, and renal biopsy confirmed the presence of vasculitis. The other patient died of unrelated disease before further evaluation could be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic sclerosis sine scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients in whom a diagnosis of systemic sclerosis is eventually made do not have obvious skin induration (\"sine scleroderma\"). The diagnosis of systemic sclerosis in these patients rests upon the presence of other characteristic clinical features (eg, Raynaud phenomenon, esophageal hypomotility, nailfold microvascular changes, and evidence of pulmonary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal involvement) and specific autoantibodies. More extensive investigation of potentially involved viscera may be required to confirm the diagnosis.",
"   </p>",
"   <p>",
"    The extracutaneous clinical features in these patients are similar to those seen in limited cutaneous systemic sclerosis (LcSSc). In an observational study of 555 consecutive systemic sclerosis patients without diffuse cutaneous involvement, 9 percent had findings of systemic sclerosis sine scleroderma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43095/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinical and laboratory features of systemic sclerosis in these patients were indistinguishable from those in patients with LcSSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of systemic sclerosis is related to the salient clinical features of the particular patient. In some cases, the differential includes conditions with scleroderma-like skin changes, whereas in others, the differential of Raynaud phenomenon or interstitial lung disease may need to be considered.",
"   </p>",
"   <p>",
"    The coexistence of Raynaud phenomenon and gastroesophageal reflux together is strongly suggestive of the diagnosis of systemic sclerosis. However, because each of these disorders occurs frequently in otherwise healthy persons or in association with various diseases, drugs, and environmental exposures, their presence is of limited diagnostic usefulness. The combination of pitting scars at the fingertips and evidence of interstitial lung disease prominent at the lung bases is also strongly suggestive of the diagnosis of systemic sclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Causes of scleroderma-like skin changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hard and indurated skin (scleroderma) may be a manifestation of diseases other than systemic sclerosis or may result from exposures to drugs, toxins, or harmful environmental factors. Some endocrine disorders (eg, diabetes mellitus and hypothyroidism), renal disease, and infiltrative disorders can also cause scleroderma-like skin changes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scleredema &mdash; Scleredema is characterized by prominent symmetrical skin thickening predominantly on the trunk, particularly the shoulders and back. The face may also be affected. In severe cases, mobility of the shoulders and chest is markedly impaired. Patients with insulin-dependent diabetes mellitus may develop a type of scleredema called scleredema of Buschke. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H31#H31\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Scleromyxedema and scleredema'",
"      </a>",
"      .) Raynaud phenomenon and autoantibodies are not present in these patients, and internal organ involvement is rare.",
"     </li>",
"     <li>",
"      Scleromyxedema &mdash; Scleromyxedema (papular mucinosis) is characterized by waxy yellow-red papules on the head, neck, arms, and upper trunk, commonly occurring over thickened and indurated skin. Middle-aged adults are most commonly affected. The presence of a monoclonal protein, often IgG lambda, detected by immunofixation on samples of serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine supports the diagnosis of scleromyxedema. Skin biopsy is valuable. Scleromyxedema may be associated with AL amyloidosis and multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H31#H31\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Scleromyxedema and scleredema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Overlap syndromes &mdash; Typical scleroderma skin changes occur in some patients with SLE and some individuals with inflammatory muscle diseases. An \"overlap syndrome\" is present if there is clear cut scleroderma together with sufficient clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory features to support a concurrent diagnosis of another defined connective tissue disease. In some cases, a diagnosis of mixed connective tissue disease is made, but this may reflect a temporary state. Many patients who are given the diagnosis of mixed connective tissue disease 'differentiate' over time into systemic sclerosis, SLE, or dermatomyositis, while some retain features of multiple diseases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"       \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=see_link\">",
"       \"Definition and diagnosis of mixed connective tissue disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endocrine disorders &mdash; Diabetes mellitus and myxedema due to hypothyroidism can be accompanied by skin induration. Endocrine disorders may also occur in some patients with monoclonal gammopathies, for example, in the POEMS syndrome (",
"      <strong>",
"       P",
"      </strong>",
"      olyneuropathy,",
"      <strong>",
"       O",
"      </strong>",
"      rganomegaly,",
"      <strong>",
"       E",
"      </strong>",
"      ndocrinopathy,",
"      <strong>",
"       M",
"      </strong>",
"      onoclonal gammopathy, and",
"      <strong>",
"       S",
"      </strong>",
"      kin changes). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sclerodactyly due to diabetes mellitus (\"diabetic cheiroarthropathy\") occurs in individuals with long-standing Type I diabetes. It is characterized by thickening and waxiness of the skin mostly marked on the dorsa of the fingers. Diabetic cheiroarthropathy is often associated with limited joint mobility. Raynaud phenomena, ischemic skin ulceration, calcinosis cutis, and tapering of the digits are absent, and autoantibodies are not detected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=see_link&amp;anchor=H6#H6\">",
"       \"Musculoskeletal complications in diabetes mellitus\", section on 'Diabetic sclerodactyly'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Myxedema is seen in hypothyroidism and is characterized by thickening and coarseness of the skin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations of hypothyroidism\", section on 'Skin'",
"      </a>",
"      .) The increased incidence of hypothyroidism in scleroderma complicates the differential diagnosis.",
"     </li>",
"     <li>",
"      Nephrogenic systemic fibrosis &mdash; Among patients with advanced renal failure (dialysis-dependent or estimated glomerular filtration rate of less than 15",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      the administration of gadolinium containing contrast media for magnetic resonance imaging has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis (previously called nephrogenic fibrosing dermopathy). Nephrogenic systemic fibrosis is characterized by involvement of skin that can mimic scleroderma or scleromyxedema. Internal organ fibrosis may also occur. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The skin involvement is characterized by two primary features:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thickening and hardening of the skin overlying the extremities and trunk.",
"     </li>",
"     <li>",
"      On histologic examination, there is marked expansion and fibrosis of the dermis, in association with CD34-positive fibroblasts.",
"     </li>",
"     <li>",
"      The clinical appearance of the affected limbs resembles eosinophilic fasciitis, but is distinguished by involvement of hands and feet, which is not seen in eosinophilic fasciitis (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis &mdash; Amyloid infiltration of the skin may produce thickening and stiffness. This is characteristic of AL amyloid, due to a plasma cell disorder. Skin biopsy reveals accumulation of amyloid with characteristic staining properties, and polarizing microscopic examination of Congo red-stained skin or subcutaneous fat reveals apple-green birefringence. Immunofixation of serum or urine often reveals a monoclonal component. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link\">",
"       \"An overview of amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic fasciitis &mdash; Eosinophilic fasciitis (Shulman's syndrome or diffuse fasciitis with eosinophilia) leads to adherence of skin to underlying fascia. Changes are prominent proximal to the wrists and ankles and usually spare the hands and feet. The disorder is associated with transient peripheral blood eosinophilia and a variable degree of inflammatory cell infiltration in the fascia. Skin changes suggestive of eosinophilic fasciitis are an orange peel (peau d'orange) appearance and the groove sign (visible collapse of the superficial veins when the limb is elevated). In order to observe the characteristic changes in the fascia, a surgical excisional biopsy of skin, including subcutaneous tissue and fascia, is necessary. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=see_link\">",
"       \"Eosinophilic fasciitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic graft-versus-host disease &mdash; Both localized and generalized scleroderma-like skin changes can occur in chronic graft-versus-host (GVH) disease. This disorder typically follows allogeneic hematopoietic transplantation but may also occur following transfusions in immunosuppressed hosts. Autoantibodies, particularly antinucleolar and antimitochondrial antibodies, may be present. Raynaud phenomenon is generally absent. Characteristic findings on skin biopsy may help in differentiating chronic GVH disease from scleroderma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced scleroderma &mdash; Use of some drugs has been linked to the development of scleroderma or scleroderma-like disorders. Reports include SSc-like changes in patients who have received the cancer chemotherapeutic drugs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , and localized scleroderma-like injection site reactions to vitamin K, vitamin B12, and the analgesic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link&amp;anchor=H15#H15\">",
"       \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'Drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H19#H19\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Subacute cutaneous lupus erythematosus and scleroderma-like changes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Environmental exposure &mdash; Use of vibrating tools may lead to Raynaud phenomenon, dissolution of the bone at the fingertips (acroosteolysis), and sclerodactyly. Exposures to organic solvents, petroleum distillates, a contaminant of L-tryptophan, and adulterated cooking oil have also been related to diseases with scleroderma-like skin thickening. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link&amp;anchor=H10#H10\">",
"       \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'Noninfectious environmental factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon in present in over 90 percent of patients with systemic sclerosis but does not occur in the other disorders associated with scleroderma-like skin changes discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Causes of scleroderma-like skin changes'",
"    </a>",
"    above.) On the other hand, cold-induced digital vasospasm may occur in isolation (primary Raynaud phenomenon), in other disease states, and in response to drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental exposures (",
"    <a class=\"graphic graphic_algorithm graphicRef62965 \" href=\"mobipreview.htm?21/28/21952\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .) Primary Raynaud phenomenon is common, affecting up to 5 percent of the general population; in these individuals, it generally develops in the first two decades of life and is not associated with digital ulcers or infarction.",
"   </p>",
"   <p>",
"    Raynaud phenomenon is not a feature of localized forms of scleroderma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of scleroderma disorders\", section on 'Localized scleroderma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extracutaneous involvement in systemic sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of typical skin features of LcSSc or DcSSc, it can be difficult to attribute internal organ involvement as due to systemic sclerosis sine scleroderma. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Systemic sclerosis sine scleroderma'",
"    </a>",
"    above.) In this setting, the absence of serologic abnormalities (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Laboratory tests'",
"    </a>",
"    above) argues against the diagnosis of systemic sclerosis.",
"   </p>",
"   <p>",
"    In rare patients with SSc, scleroderma renal crisis may be the initial disease manifestation, preceding skin changes. The approach to the differential diagnosis of ischemic or fibrotic involvement limited to a particular organ is presented separately in appropriate topic reviews. Examples include interstitial lung",
"    <span class=\"nowrap\">",
"     disease/pulmonary",
"    </span>",
"    fibrosis, primary and secondary pulmonary arterial hypertension, and renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35801?source=see_link&amp;anchor=H13#H13\">",
"     \"Scleroderma renal crisis\", section on 'Diagnosis and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/23/28017?source=see_link\">",
"       \"Patient information: Scleroderma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of systemic sclerosis is primarily based upon the presence of characteristic clinical findings.",
"     </li>",
"     <li>",
"      Thickening and hardening of the skin in systemic sclerosis must be differentiated from skin changes in other disease states. A thorough history of drug, toxin, and environmental exposures; a clinical assessment for diabetes mellitus, systemic lupus erythematosus, or myositis; and serologic testing for the presence of autoantibodies are useful in excluding these as causes of skin thickening. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Causes of scleroderma-like skin changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful assessment of the extent and distribution of skin involvement allows classification of SSc patients into subsets of limited cutaneous systemic sclerosis (LcSSc) and diffuse cutaneous systemic sclerosis (DcSSc), which has important prognostic implications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"       \"Classification of scleroderma disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some patients with SSc, scleroderma renal crisis may be the initial disease manifestation, preceding skin changes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Extracutaneous involvement in systemic sclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extracutaneous manifestations of systemic sclerosis may occur in the absence of scleroderma. In early disease, skin or soft tissue swelling may precede skin hardening. Likewise, Raynaud phenomenon, though generally noted prior to or at initial presentation, may be absent in early diffuse cutaneous systemic sclerosis (DcSSc). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic sclerosis sine scleroderma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence of extracutaneous disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic tests are helpful in confirming but not in excluding a diagnosis of systemic sclerosis, and certain autoantibodies may be predictive of specific clinical manifestations. The following autoantibody testing is suggested in patients with suspected systemic sclerosis: antinuclear antibody (ANA) screening and specific tests for antitopoisomerase I (anti-Scl-70), anticentromere (ACA), anti-RNA polymerase III, and anti-beta2-glycoprotein I antibodies. The antitopoisomerase I, ACA, and anti-RNA polymerase III antibody tests are highly specific but only moderately sensitive. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum and urine protein electrophoresis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunofixation are recommended in patients with symmetrical skin induration not associated with Raynaud phenomenon in order to exclude disorders associated with monoclonal gammopathies that are considered in the differential diagnosis (eg, the POEMS syndrome, scleromyxedema, and amyloidosis). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Causes of scleroderma-like skin changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin biopsy is generally not necessary to confirm a clinical diagnosis of systemic sclerosis. However, skin biopsy is suggested if the diagnosis is in doubt. Biopsy can differentiate between systemic sclerosis and the other disorders associated with scleroderma-like skin changes. The biopsy should include subcutaneous tissue, fascia, and muscle if possible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Causes of scleroderma-like skin changes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/1\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/2\">",
"      Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/3\">",
"      Russo K, Hoch S, Dima C, et al. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J Rheumatol 2000; 27:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/4\">",
"      Kuwana M, Okano Y, Pandey JP, et al. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005; 52:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/5\">",
"      Walker UA, Tyndall A, Czirj&aacute;k L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/6\">",
"      Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/7\">",
"      Sacks DG, Okano Y, Steen VD, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996; 23:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/8\">",
"      Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/9\">",
"      Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992; 35:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/10\">",
"      Boin F, Franchini S, Colantuoni E, et al. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009; 60:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/11\">",
"      Nguyen B, Mayes MD, Arnett FC, et al. HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/12\">",
"      Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/13\">",
"      Satoh M, Kuwana M, Ogasawara T, et al. Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol 1994; 153:5838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/14\">",
"      Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58:3902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/15\">",
"      Locke IC, Worrall JG, Leaker B, et al. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997; 24:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/16\">",
"      Merkel PA, Polisson RP, Chang Y, et al. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43095/abstract/17\">",
"      Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7539 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43095=[""].join("\n");
var outline_f42_5_43095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF SYSTEMIC SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evidence of extracutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic sclerosis sine scleroderma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Causes of scleroderma-like skin changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extracutaneous involvement in systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7539|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/28/21952\" title=\"algorithm 1\">",
"      Approach to dx of Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7539|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/38/608\" title=\"picture 1\">",
"      Nailfold capillaroscopy in SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/13/43224\" title=\"picture 2\">",
"      ANA staining patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/18/10541\" title=\"table 1\">",
"      Autoantibodies in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=related_link\">",
"      Eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/23/28017?source=related_link\">",
"      Patient information: Scleroderma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43096="Risk factors and development of atherosclerosis in childhood";
var content_f42_5_43096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors and development of atherosclerosis in childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43096/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/5/43096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiovascular disease (CVD) is generally manifest in adulthood, the process of atherosclerosis can begin early in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/1\">",
"     1",
"    </a>",
"    ]. For most children, atherosclerotic vascular changes are minor and can be minimized or even prevented with adherence to a healthy lifestyle. However, in some children, the process is accelerated because of the presence of identifiable risk factors (eg, obesity and hypertension)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specific diseases that are associated with premature CVD (eg, diabetes mellitus and Kawasaki disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence linking atherosclerotic changes in childhood to CVD will be reviewed here. In addition, risk factors in childhood that are associated with early atherosclerosis and CVD will also be discussed.",
"   </p>",
"   <p>",
"    Primary pediatric intervention to reduce or minimize atherosclerosis, and identifying and managing the child at risk for atherosclerosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATHEROSCLEROTIC CHANGES IN CHILDHOOD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H161661927\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the development of atherosclerosis in childhood consists of pediatric evidence of direct autopsy studies showing atherosclerotic changes and indirect data showing vascular changes associated with adult cardiovascular disease (CVD).",
"   </p>",
"   <p>",
"    In addition, these studies demonstrate an association between premature atherosclerosis and well-established adult CVD risk factors (eg,",
"    <span class=\"nowrap\">",
"     overweight/obesity,",
"    </span>",
"    hypertension, dyslipidemia, and smoke exposure).",
"   </p>",
"   <p>",
"    These data, along with evidence from adult studies, are the basis for promoting healthy pediatric cardiovascular lifestyle by preventing and reducing risk factors associated with premature atherosclerosis and, by extension, CVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31442039\">",
"    <span class=\"h2\">",
"     Direct autopsy evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies in children and young adults who have died of noncardiovascular causes demonstrate direct evidence of early development of atherosclerosis, with findings of fatty streaks (accumulation of lipid-filled macrophages within the intima of the artery, which are early atherosclerotic changes) and fibrous plaque (a more advanced stage of atherosclerosis), as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Bogalusa Heart Study, autopsies performed in 204 young subjects (2 to 39 years of age, mean age 19.6 years), demonstrated fatty streaks in 50 percent of cases between 2 and 15 years of age, and in 85 percent of older subjects between 21 and 39 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/3\">",
"       3",
"      </a>",
"      ]. The prevalence of raised fibrous plaques in the aorta and coronary arteries also increased with age from about 20 percent in subjects between 2 and 15 years of age to 70 percent in those between 26 and 39 years of age. The prevalence and the extent of atherosclerosis found in the aorta and coronary arteries were greater with increasing body-mass index (BMI), blood pressure measurements, and levels of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). The degree of involvement increased with worsening severity and greater numbers of risk factors.",
"     </li>",
"     <li>",
"      The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study examined the right coronary arteries and aortas in autopsies of 2876 individuals between 15 and 34 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In subjects who were 15 to 19 years of age, raised fatty streaks (accumulations of lipid-filled macrophages within the intima of the artery) were present in 10 percent of coronary arteries and 30 percent of aortas. The extent of fatty streaks increased with older age, elevated blood pressure, higher serum low-density lipoprotein cholesterol (LDL-C), and lower serum high-density lipoprotein cholesterol (HDL-C). Female patients lagged by five years behind male patients in the progression of the extent of raised lesions in the right coronary arteries. In a subsequent report, individuals with early and more severe atherosclerotic changes were more likely to have had one or more of the following known adult cardiovascular disease (CVD) risk factors: dyslipidemia, smoking, hypertension, obesity, and hyperglycemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, comparison between data from the PDAY cohort and population-based data on cardiovascular (CV) risk factors that were obtained concurrently suggest the prevalence of identified risk factors from the PDAY study are mirrored in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235229608\">",
"    <span class=\"h2\">",
"     Indirect evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents, indirect evidence for early development of atherosclerosis is found in studies that detected vascular changes, which are associated with CVD in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These include changes in vessel anatomy (ie, increased intima media thickness [IMT] and coronary calcification), mechanical changes (ie, decreased arterial distensibility or increased stiffness), and physiologic changes (ie, decreased flow mediated vasodilatation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid intima media thickness &ndash; Young adults with increased carotid IMT detected by ultrasonography have an increased likelihood of a cardiovascular event (ie, myocardial infarction and stroke). In addition, increased IMT is found in adolescents with familial hyperlipidemia, in children with a parent with a history of premature myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/10\">",
"       10",
"      </a>",
"      ], and in children with diseases associated with a high-risk of CVD, such as type 1 diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/11\">",
"       11",
"      </a>",
"      ]. Cardiovascular risk factors (ie, overweight, dyslipidemia, and hypertension) are predictive of increased carotid IMT in young adults and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/12-16\">",
"       12-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arterial stiffness &ndash; Arterial stiffness is measured as the speed at which an aortic pulse travels between two major arteries, one of which is located in the upper body (ie, carotid or brachial artery) and the other in the lower body (ie, femoral or ankle). In adults, increased arterial stiffness is associated with a higher likelihood of CVD. Arterial stiffness normally varies among adolescents and young adults based upon gender, age, and ethnicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/17\">",
"       17",
"      </a>",
"      ]. After adjusting for age and gender, arterial stiffness in adolescents and young adults is associated with CVD risk factors (ie, increased body-mass index, hypertension, and elevated serum triglyceride, homocysteine, and fasting insulin concentrations) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/17-19\">",
"       17-19",
"      </a>",
"      ] and correlates positively with left ventricular mass (LVM), independent of other CVD risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/20\">",
"       20",
"      </a>",
"      ]. In one study of 670 adolescents and young adults (age range 10 to 24 years) stratified into three groups based upon BMI (lean [BMI &lt;85",
"      <sup>",
"       th",
"      </sup>",
"      percentile], obese [BMI &ge;85",
"      <sup>",
"       th",
"      </sup>",
"      percentile], and obese with type 2 diabetes [T2DM]), there was a progressive increase in arterial stiffness from the lean group to the obese and",
"      <span class=\"nowrap\">",
"       obese/T2DM",
"      </span>",
"      groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. After adjusting for other CV risk factors, central obesity remained an independent predictor for arterial stiffness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H10122167#H10122167\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial stiffness'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flow-mediated dilation &ndash; Flow-mediated dilation measures the endothelial response to an adverse stimulus (eg, ischemia induced by an inflated blood pressure cuff) by brachial artery ultrasonography (also referred to as brachial artery reactivity). Brachial artery reactivity is lower in children with type 1 diabetes mellitus, a family history of premature coronary disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/10\">",
"       10",
"      </a>",
"      ], and Kawasaki disease with aneurysms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link&amp;anchor=H11#H11\">",
"       \"Endothelial dysfunction\", section on 'Brachial artery ultrasound'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1257700\">",
"    <span class=\"h3\">",
"     Longitudinal prospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three longitudinal studies have demonstrated an association between the presence of established risk factors for CVD (ie, elevated LDL-C, obesity, hypertension, smoke exposure, and diabetes) during childhood and evidence of early atherosclerotic changes in adulthood based on the above measures that detect vascular changes. Similar findings were found in a fourth study of young adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bogalusa study &ndash; In a cohort of 486 adults (age range 25 to 37 years), childhood measurements of LDL-C levels and BMI positively predicted carotid IMT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscatine study &ndash; In a cohort of 725 adults (age range 33 to 42 years), childhood total cholesterol levels positively predicted carotid IMT, and in women, childhood BMI was also a significant predictor of IMT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiovascular Risk in Young Finns study &ndash; In a cohort of Finnish patients followed for 27 years, IMT increased as the number of CV risk factors increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/23\">",
"       23",
"      </a>",
"      ]. In particular, elevated childhood levels of LDL-C and insulin, and pediatric obesity were predictive of increased IMT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/24\">",
"       24",
"      </a>",
"      ]. In subsequent studies, carotid artery elasticity decreased as the number of childhood CV risk factors increased, and flow-mediated dilation was lower in male patients who had elevated blood pressure during adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CARDIA (Coronary Artery Risk Development in Young Adults) study &ndash; In a cohort of patients initially recruited at 18 to 30 years of age followed for 15 years, smoking, increasing levels of LDL-C and glucose, and increasing systolic blood pressure were associated with increased risk of detecting coronary artery calcium by computed tomography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study that combined data from the above four prospective studies, the number of childhood risk factors (eg, cholesterol, triglycerides, blood pressure, and BMI) was predictive of elevated adult intima-media thickness on the basis of risk factors measured at age 9 years (odds ratio [OR] 1.37, 95% CI 1.16-1.61), 12 years (OR 1.48, 95% CI 1.28-1.72), 15 years (OR 1.56, 95% CI 1.36-1.78), and 18 years (OR 1.57, 95% CI 1.31-1.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/16\">",
"     16",
"    </a>",
"    ]. Another review of three of these studies confirmed dyslipidemia in adolescence was predictive of increased IMT with relative risks that range from 1.6 to 2.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169814611\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, several large prospective population-based studies have shown that multiple risk factors (eg, increased body mass index [BMI], hypertension, dyslipidemia, and family history of cardiovascular disease [CVD]) are associated with higher risk of CVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While data linking these risk factors to cardiovascular (CV) events are limited in children, these risk factors, as discussed previously, are associated with acceleration of atherosclerosis in children based on autopsy data and indirect measures of CVD (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Atherosclerotic changes in childhood'",
"    </a>",
"    above). In addition, longitudinal studies demonstrate a reasonably strong correlation between childhood blood pressure, serum lipid levels, and BMI with analogous values measured in middle age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, children with CVD risk factors are more likely to be at-risk adults.",
"   </p>",
"   <p>",
"    Children with specific disease states (eg, familial hypercholesterolemia, diabetes mellitus, and renal failure) also are more likely to develop premature atherosclerosis and CVD at an earlier age, with some patients experiencing CV events during childhood or adolescence. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk diseases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The United States (US) analysis of 3383 adolescents (ages 12 to 19 years) who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 through 2008 showed the prevalence for the following CVD risk factors or associated diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Prehypertension/hypertension",
"      </span>",
"      &ndash; 14 percent",
"     </li>",
"     <li>",
"      Borderline",
"      <span class=\"nowrap\">",
"       high/high",
"      </span>",
"      levels of low-density lipoprotein cholesterol &ndash; 22 percent",
"     </li>",
"     <li>",
"      Low levels of high-density lipoprotein cholesterol &ndash; 6 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Prediabetes/diabetes",
"      </span>",
"      &ndash; 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study using NHANES III data of participants (12 to 39 years of age) enrolled from 1988 to 1994, multivariate analysis, which adjusted for age, gender, and",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    demonstrated the CVD risk factors of diabetes (eg, high hemoglobin AIc levels), central obesity, and smoking were associated with an increased risk for death before 55 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/31\">",
"     31",
"    </a>",
"    ]. Because there were relatively few deaths, it was not possible to determine whether these factors were associated with specific causes of death (eg, cardiovascular deaths).",
"   </p>",
"   <p>",
"    Risk factors and diseases associated with premature atherosclerosis do not generally occur in isolation, but are usually found concurrently, which increases the risk of premature atherosclerosis and CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/3,16,23,30\">",
"     3,16,23,30",
"    </a>",
"    ]. As an example, in the above NHANES study, the risk of any CVD risk factor rose with increasing BMI as follows: 37, 49, and 61 percent for normal weight, overweight, and obese adolescents, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, the risk of having three or more CVD risk factors rose with increasing BMI: 1, 2, and 8 percent for normal weight, overweight, and obese adolescents, respectively. These data highlight the high prevalence of CVD risk factors in adolescents in the US, especially overweight or obese individuals.",
"   </p>",
"   <p>",
"    Similar results showing the effect of elevated BMI on other CVD risk factors were seen in a meta-analysis of 63 studies of 49,220 children, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure was higher in overweight (4.54 mmHg, 95% CI 2.44-6.64) and obese children (7.49 mmHg, 95% CI 3.36-11.62) compared with normal weight children.",
"     </li>",
"     <li>",
"      Total cholesterol (6",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      95% CI 2-10 [0.15",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      95% CI 0.04-0.25]) and triglycerides (23",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      95% CI 12-25 [0.26 mmol, 95% 0.13-0.39]) were higher in obese compared with normal weight children.",
"     </li>",
"     <li>",
"      Left ventricular mass (LVM) was also increased in obese versus normal weight children (19.1 g, 95% CI 12.7-25.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections discuss the recognized risk factors and disease processes associated with accelerated atherosclerosis and CVD in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overweight and obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously discussed autopsy studies, body mass index (BMI) was positively correlated with more extensive atherosclerotic changes in the aorta and coronary arteries during childhood.",
"   </p>",
"   <p>",
"    There is also evidence demonstrating that higher BMI during childhood increases the risk of CVD in adulthood. This was illustrated by a large prospective cohort study of 276,835 Danish children who were born from 1930 to 1976 for whom childhood BMI measurements were available from mandatory school examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/33\">",
"     33",
"    </a>",
"    ]. Coronary heart disease (CHD) events were determined for each subject through a national registry that was established in 1968. Follow-up of subjects began at 25 years of age or in 1977. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a positive linear association between increasing BMI at every age from 7 to 13 years and the number of CHD events in both girls and boys, although the association was stronger in boys. Each 1-unit increase in BMI Z-score increased the risk of an event. The risk increased with age, and was lower for girls compared with boys. As an example, they found a 33 percent higher risk for a CHD event by 60 years of age for a 13-year-old boy who weighed 11 kg more than average compared with a 13-year-old boy of similar height but average weight. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link&amp;anchor=H5#H5\">",
"       \"Measurement of growth in children\", section on 'Z-scores'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The effect of excess weight on the risk of a CHD event rose with increasing age; for each 1-unit increase in the BMI Z-score, the risk of CHD was nearly double in 13-year-old boys compared with 7-year-old boys.",
"     </li>",
"     <li>",
"      Relatively small increases in weight were associated with increased CHD risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings",
"    <span class=\"nowrap\">",
"     expanded/extended",
"    </span>",
"    those of smaller studies that had not previously found such an association, and they remained significant after adjustment for birthweight, a factor known to affect CV risk.",
"   </p>",
"   <p>",
"    Other studies have shown that children or adolescents who are overweight (defined as BMI &ge;85",
"    <sup>",
"     th",
"    </sup>",
"    percentile) or obese (defined as BMI percentile &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile), compared with normal weight children, are more likely to be hypertensive, have dyslipidemia and insulin resistance, develop type 2 diabetes mellitus, and be overweight as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/34\">",
"     34",
"    </a>",
"    ]. As mentioned previously, adolescents and young adults (age between 10 to 24 years) who were obese and had type 2 diabetes were more likely to have increased carotid artery intimal thickness and stiffness than obese and lean patients without type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Overweight children are also inactive and have obstructive sleep apnea and increased LVM, which are all associated with CVD in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Hypertension'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Dyslipidemia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H15#H15\">",
"     \"Health hazards associated with obesity in adults\", section on 'Coronary disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H20#H20\">",
"     \"Health hazards associated with obesity in adults\", section on 'Stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=see_link&amp;anchor=H235228225#H235228225\">",
"     \"Definition and screening for dyslipidemia in children\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, most obese adolescents remain obese as adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=see_link&amp;anchor=H5#H5\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Persistence into adulthood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constellation of CVD risk factors that includes type 2 diabetes, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension, is referred to as the metabolic syndrome. In adults, metabolic syndrome is associated with an increased risk of CV events, and all cause mortality. The concept of metabolic syndrome in childhood is primarily used in research; it is not used in routine clinical care because the relationship between childhood metabolic syndrome and CVD events is not well characterized and there is no consensus on the pediatric definition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link&amp;anchor=H25#H25\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Children and adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a report using data from the National Heart, Lung, and Blood Institute Lipid Research Clinics Princeton Prevalence Study and the Princeton Follow-up Study, children between the ages of 6 to 19 years who were identified as meeting criteria for metabolic syndrome using a definition modified from the adult ATP III definition had an increased risk of CVD (OR 14.6, 95% CI 4.8-45.3) at 25-year follow-up compared with the general school population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/36\">",
"     36",
"    </a>",
"    ]. They also were more likely to have metabolic syndrome in adulthood (OR 6.2, 95% CI 2.8-13.8).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, hypertension is a well-established risk factor for adverse CV outcomes (ie, myocardial infarction and stroke). Epidemiologic studies have shown that the risk of CVD increases progressively as blood pressure rises above the threshold value of",
"    <span class=\"nowrap\">",
"     110/75.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4874043#H4874043\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, although similar direct evidence linking elevated blood pressure with CVD is lacking, essential hypertension is associated with increased carotid intima-media thickness and arterial stiffness suggestive of accelerated atherosclerosis. Children with elevated blood pressure are more likely to have hypertension in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link&amp;anchor=H10#H10\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Tracking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and treatment of hypertension in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemias are disorders of lipoprotein metabolism that result in the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High total cholesterol (TC)",
"     </li>",
"     <li>",
"      High low-density lipoprotein cholesterol (LDL-C)",
"     </li>",
"     <li>",
"      Low high-density lipoprotein cholesterol (HDL-C)",
"     </li>",
"     <li>",
"      High triglycerides (TG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although dyslipidemia is an established risk factor for CVD in adults, no long-term studies directly link dyslipidemia in childhood with subsequent CVD, with the possible exception of children with monogenetic causes of dyslipidemia such as familial hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, dyslipidemia in childhood is associated with increased risks of atherosclerotic lesions in autopsy studies, increased intima-media thickness in adulthood, and persistent adult dyslipidemia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Atherosclerotic changes in childhood'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The evaluation and management of children with abnormal lipid profiles are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of CVD is an independent risk factor for coronary CV events in adults. A positive family history is generally defined as premature coronary heart disease including heart attack, treated angina, interventions for coronary artery disease, stroke or sudden cardiac disease in a male parent or sibling before 55 years of age, or a female parent or sibling before 65 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Family history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link&amp;anchor=H4#H4\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, evidence of accelerated atherosclerosis (eg, lower brachial arterial reactivity and greater carotid intima-media thickness) is more commonly detected in adolescent offspring of individuals with premature myocardial infarction compared with controls without a family history of premature CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the sensitivity of a positive family history for detection of CVD or dyslipidemia appears to be relatively low. Several studies, for example, have shown that a positive family history can fail to detect 30 to 60 percent of children with dyslipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/38\">",
"     38",
"    </a>",
"    ], and as discussed above, the risk of dyslipidemia may be independent of a family history of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/39\">",
"     39",
"    </a>",
"    ]. However, individuals with a family history positive for early heart disease have twice the risk of CVD as those without, even after adjusting for conventional risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/40\">",
"     40",
"    </a>",
"    ]. The impact of a positive family history upon CVD is more fully discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Family history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link&amp;anchor=H4#H4\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Smoke exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoke exposure, including second-hand cigarette smoke, increases the risk of CVD. Because of its addictive nature, pediatric tobacco use increases the risk of persistent adult smoking. The risk of CVD due to smoke exposure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link&amp;anchor=H12#H12\">",
"     \"Secondhand smoke exposure: Effects in children\", section on 'Atherogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     High-risk diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific disease states are associated with early CVD and accelerated atherosclerosis. In a scientific statement from the American Heart Association (AHA), a panel of experts reviewed the literature on premature CVD in children and established disease risk stratification schema for coronary artery disease (CAD), which was revised by the National Heart, Lung and Blood Institute panel in 2011 (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/1,41\">",
"     1,41",
"    </a>",
"    ]. The following diseases were identified as those associated with an increase risk of CAD (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus, types 1 and 2",
"     </li>",
"     <li>",
"      Chronic kidney disease",
"     </li>",
"     <li>",
"      Post-heart transplantation",
"     </li>",
"     <li>",
"      Kawasaki disease with current or regressed coronary artery aneurysms",
"     </li>",
"     <li>",
"      Chronic inflammatory disease",
"     </li>",
"     <li>",
"      Cancer survivors",
"     </li>",
"     <li>",
"      Human immunodeficiency virus",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These diseases and their associations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2960855\">",
"    <span class=\"h2\">",
"     Prenatal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is emerging evidence that prenatal factors impact offspring CV health in adulthood. These include intrauterine growth retardation (IUGR), gestational diabetes, and maternal factors such as hypertension, prenatal smoking, and excessive weight gain during pregnancy. Studies have demonstrated that IUGR is associated with an increased risk of insulin-resistance, CVD risk factors (eg, dyslipidemia, hypertension, and elevated C-reactive protein), and vascular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43096/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, additional research is needed to determine the relative contribution of fetal factors compared with the known contributions of the postnatal risk factors, as discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/35/4660?source=see_link\">",
"       \"Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although cardiovascular disease (CVD) is generally manifest in adulthood, there is both direct evidence based on autopsy studies and indirect data on preclinical vascular changes demonstrating that atherosclerosis can develop early in childhood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Atherosclerotic changes in childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, indirect evidence for early development of atherosclerosis is based on studies that detected vascular changes, which are associated with atherosclerosis and CVD in adults. These indirect measures include changes in vessel anatomy (ie, increased intima media thickness, and coronary calcification), mechanical changes (ie, decreased arterial distensibility or increased stiffness), and physiologic changes (ie, decreased flow mediated vasodilatation). (See",
"      <a class=\"local\" href=\"#H235229608\">",
"       'Indirect evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Development of atherosclerosis is accelerated by the following identifiable risk factors. The presence of multiple risk factors increases the likelihood of accelerated atherosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Overweight/obesity",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Overweight and obesity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hypertension (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypertension'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Dyslipidemia (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Dyslipidemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Family history of premature CVD",
"     </li>",
"     <li>",
"      Smoking exposure (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Smoke exposure'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      High-risk diseases &ndash; At-risk conditions identified by the American Heart Association include type 1 and 2 diabetes mellitus, nephrotic syndrome, chronic renal failure, Kawasaki disease with coronary aneurysms, other rheumatologic or inflammatory disorders, childhood cancer, select types of congenital heart disease, and overweight (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'High-risk diseases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link\">",
"       \"Diseases associated with atherosclerosis in childhood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/1\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/2\">",
"      American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/3\">",
"      Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/4\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/5\">",
"      McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998; 82:30T.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/6\">",
"      McMahan CA, Gidding SS, Malcom GT, et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006; 118:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/7\">",
"      McMahan CA, Gidding SS, Malcom GT, et al. Comparison of coronary heart disease risk factors in autopsied young adults from the PDAY Study with living young adults from the CARDIA study. Cardiovasc Pathol 2007; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/8\">",
"      Groner JA, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics 2006; 118:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/9\">",
"      Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res 2005; 58:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/10\">",
"      Gaeta G, De Michele M, Cuomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/11\">",
"      Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2006; 74:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/12\">",
"      Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/13\">",
"      Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/14\">",
"      Raitakari OT, Juonala M, K&auml;h&ouml;nen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/15\">",
"      Dawson JD, Sonka M, Blecha MB, et al. Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: the Muscatine Offspring Study. J Am Coll Cardiol 2009; 53:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/16\">",
"      Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010; 122:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/17\">",
"      Alpert BS, Collins RT. Assessment of vascular function: pulse wave velocity. J Pediatr 2007; 150:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/18\">",
"      Im JA, Lee JW, Shim JY, et al. Association between brachial-ankle pulse wave velocity and cardiovascular risk factors in healthy adolescents. J Pediatr 2007; 150:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/19\">",
"      Li S, Chen W, Srinivasan SR, Berenson GS. Childhood blood pressure as a predictor of arterial stiffness in young adults: the bogalusa heart study. Hypertension 2004; 43:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/20\">",
"      Urbina EM, Dolan LM, McCoy CE, et al. Relationship between elevated arterial stiffness and increased left ventricular mass in adolescents and young adults. J Pediatr 2011; 158:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/21\">",
"      Urbina EM, Kimball TR, Khoury PR, et al. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens 2010; 28:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/22\">",
"      Urbina EM, Kimball TR, McCoy CE, et al. Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. Circulation 2009; 119:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/23\">",
"      Juonala M, Viikari JS, K&auml;h&ouml;nen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. Eur Heart J 2010; 31:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/24\">",
"      Koskinen J, K&auml;h&ouml;nen M, Viikari JS, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation 2009; 120:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/25\">",
"      Juonala M, J&auml;rvisalo MJ, M&auml;ki-Torkko N, et al. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation 2005; 112:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/26\">",
"      Juonala M, Viikari JS, R&ouml;nnemaa T, et al. Elevated blood pressure in adolescent boys predicts endothelial dysfunction: the cardiovascular risk in young Finns study. Hypertension 2006; 48:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/27\">",
"      Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol 2007; 49:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/28\">",
"      Magnussen CG, Venn A, Thomson R, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol 2009; 53:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/29\">",
"      Juhola J, Magnussen CG, Viikari JS, et al. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr 2011; 159:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/30\">",
"      May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics 2012; 129:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/31\">",
"      Saydah S, Bullard KM, Imperatore G, et al. Cardiometabolic Risk Factors Among US Adolescents and Young Adults and Risk of Early Mortality. Pediatrics 2013; 131:e679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/32\">",
"      Friedemann C, Heneghan C, Mahtani K, et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ 2012; 345:e4759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/33\">",
"      Baker JL, Olsen LW, S&oslash;rensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007; 357:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/34\">",
"      van Dam RM, Willett WC, Manson JE, Hu FB. The relationship between overweight in adolescence and premature death in women. Ann Intern Med 2006; 145:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/35\">",
"      Steinberger J, Daniels SR, Eckel RH, et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009; 119:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/36\">",
"      Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/37\">",
"      Al-Shaikh AM, Abdullah MH, Barclay A, et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young 2002; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/38\">",
"      Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007; 120:e189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/39\">",
"      Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics 2010; 126:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/40\">",
"      Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/41\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/42\">",
"      Skilton MR, Viikari JS, Juonala M, et al. Fetal growth and preterm birth influence cardiovascular risk factors and arterial health in young adults: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 2011; 31:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43096/abstract/43\">",
"      Thompson JA, Regnault TR. In utero origins of adult insulin resistance and vascular dysfunction. Semin Reprod Med 2011; 29:211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5781 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43096=[""].join("\n");
var outline_f42_5_43096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATHEROSCLEROTIC CHANGES IN CHILDHOOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H161661927\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31442039\">",
"      Direct autopsy evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H235229608\">",
"      Indirect evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1257700\">",
"      - Longitudinal prospective studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169814611\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overweight and obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      High-risk diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2960855\">",
"      Prenatal factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5781|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/35/4660?source=related_link\">",
"      Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43097="Allergic reactions to vaccines";
var content_f42_5_43097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic reactions to vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     John M Kelso, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/5/43097/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/5/43097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe allergic reactions to vaccines are rare and difficult to predict. An allergic reaction may be defined as an idiosyncratic reaction that is caused by an immunologic mechanism.",
"   </p>",
"   <p>",
"    The World Allergy Organization (WAO) has recommended categorizing immunologic reactions to drugs (including vaccines) based upon the timing of the appearance of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/1\">",
"     1",
"    </a>",
"    ]. This system defines two general types of reactions: immediate and delayed. This approach is intended to distinguish IgE-mediated (type I immunologic reactions), which account for many immediate reactions, from other types, because these reactions carry the risk of life-threatening anaphylaxis if the patient is reexposed (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions begin within one hour of administration and may begin within minutes. IgE-mediated reactions are most likely to present within this time period.",
"     </li>",
"     <li>",
"      Delayed reactions appear several hours to days after administration. These reactions may be caused by several different mechanisms, but they are rarely IgE-mediated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review focuses on immediate-type allergic reactions to vaccines, although delayed reactions are also discussed briefly. Of note, the administration of influenza vaccine to egg-allergic patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .) Additional information about other types of adverse reactions to immunization, including unsubstantiated concerns about autism, is found in reviews of specific vaccines, elsewhere within UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4744788\">",
"    <span class=\"h2\">",
"     Immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate, IgE-mediated allergic reactions may involve various combinations of up to 40 potential symptoms and signs (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common symptoms and signs are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous symptoms, including flushing, itching, urticaria, and angioedema",
"     </li>",
"     <li>",
"      Respiratory symptoms, including nasal discharge, nasal congestion, change in voice quality, sensation of throat closure or choking, stridor, cough, wheeze, and dyspnea",
"     </li>",
"     <li>",
"      Cardiovascular symptoms, including faintness, syncope, altered mental status, palpitations, and hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Definition of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most severe form of an IgE-mediated allergic reaction is anaphylaxis. Anaphylaxis is defined as a systemic allergic reaction that is rapid in onset and may cause death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/2\">",
"     2",
"    </a>",
"    ]. Anaphylactic reactions to vaccines are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/3\">",
"     3",
"    </a>",
"    ]. Typically, they occur when a person has developed preformed IgE antibodies to a vaccine constituent, rather than to the immunizing agent itself.",
"   </p>",
"   <p>",
"    Diagnostic criteria for anaphylaxis have been proposed by the National Institute of Allergy and Infectious",
"    <span class=\"nowrap\">",
"     Disease/Food",
"    </span>",
"    Allergy and Anaphylaxis Network symposium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/2\">",
"     2",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 3",
"    </a>",
"    ). The diagnosis of anaphylaxis is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When anaphylaxis occurs after administration of a vaccine, patients generally develop symptoms within 5 to 30 minutes. Less commonly, the onset of symptoms of anaphylaxis may be delayed up to several hours.",
"   </p>",
"   <p>",
"    The temporal relationship between an allergic reaction and the administration of a vaccine was documented in a study of children who received MMR vaccine and subsequently experienced allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the 17 children whose reactions were characterized as anaphylaxis, all but one began within 15 minutes of vaccine administration. By comparison, less severe allergic reactions (principally urticaria or asthma) occurred hours to days after vaccine administration. Some of these late reactions may not have been causally related to vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Delayed vaccine reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of delayed reactions to vaccines have been noted, including common reactions like fever or local swelling, and various rare reactions. These may be immunologic or non-immunologic in nature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fever",
"      </strong>",
"      : Fever and irritability are common after vaccination and should not preclude additional doses of the same vaccine in the future [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Local reactions",
"      </strong>",
"      : Local reactions to vaccination, such as swelling and redness at the injection site are common and self-limited. These should not be considered reasons for avoiding administration of further doses of the vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5\">",
"       5",
"      </a>",
"      ]. Local reactions can be treated with cool compresses for the first hours after symptoms appear, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or NSAIDs if pain or swelling is troublesome. However, antipyretics should not be administered empirically or prophylactically, as at least one study found that these medications may reduce the immune response to vaccination. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H7#H7\">",
"       \"Standard immunizations for children and adolescents\", section on 'Prophylactic acetaminophen'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It was believed that shorter intervals between vaccine doses were associated with increased rates of local reactions, although studies have now shown that this is not the case. The recommended interval between doses of tetanus-containing vaccines had been 10 years. New vaccines were recommended in 2006 to provide not only booster doses for tetanus and diphtheria (Td), but also to pertussis (Tdap) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Two subsequent studies reported rates of local reactions in patients given the new vaccine. In one, the rates of injection site reactions to Tdap were no different among subjects who had received Td within the past two years, compared with those vaccinated with Td more than two years before [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/8\">",
"       8",
"      </a>",
"      ]. Another study found no higher rates of injection site reactions whether a Tdap-containing vaccine was administered one month after a Td-containing vaccine or after placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/9\">",
"       9",
"      </a>",
"      ]. It is now recommended that Tdap be given to all adolescents and adults regardless of interval since the last Td [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other rare reactions:",
"      </strong>",
"      Delayed immunologic reactions include rare cases of erythema nodosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/11-14\">",
"       11-14",
"      </a>",
"      ]. Another rare reaction is encephalopathy, which is considered non-immunologic. Some of these more severe reactions may constitute contraindications to further doses of specific vaccines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4744967\">",
"    <span class=\"h2\">",
"     Vasovagal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine administration may elicit vasovagal reactions (fainting), particularly in patients who are prone to this response. Vasovagal reactions are characterized by hypotension, pallor, diaphoresis, weakness, nausea, vomiting, bradycardia, and if severe, by loss of consciousness.",
"   </p>",
"   <p>",
"    Vasovagal reactions can mimic anaphylaxis, because both may involve hypotension and collapse. However, the cutaneous signs and symptoms are usually quite different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/15\">",
"     15",
"    </a>",
"    ]. Fainting is usually preceded by pallor, where as anaphylaxis often begins with flushing and may also include itching, urticaria, and angioedema. In anaphylaxis, tachycardia is more common than bradycardia.",
"   </p>",
"   <p>",
"    In patients who report past fainting in response to vaccinations, it is prudent to administer future vaccines while the patient is lying supine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REACTIONS TO VACCINE CONSTITUENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different nonmicrobial constituents of vaccines can result in systemic allergic reactions, including anaphylaxis. Possible sources of allergenic proteins in vaccines include gelatin, egg, chicken, preservatives, antimicrobial agents, yeast, and natural rubber latex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3417929\">",
"    <span class=\"h2\">",
"     Sources of information",
"    </span>",
"    &nbsp;&mdash;&nbsp;A list of potential allergens contained in vaccines is maintained by the Institute for Vaccine Safety and is available on the Internet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the US Centers for Disease Control (CDC) provides tables of vaccine excipients, categorized both by vaccine and by excipient, which can be found at:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organized by vaccine:",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf\">",
"       www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf",
"      </a>",
"     </li>",
"     <li>",
"      Organized by excipient:",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-1.pdf\">",
"       www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-1.pdf",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gelatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gelatin, which is added to many vaccines as a stabilizer, is responsible for many anaphylactic reactions to measles, mumps, and rubella (MMR), varicella, and Japanese encephalitis vaccines (a new Japanese encephalitis vaccine does not contain gelatin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3417929\">",
"     'Sources of information'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anaphylaxis from gelatin in influenza vaccine has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, a history of allergy to the ingestion of gelatin and gelatin-containing foods (eg, marshmallows and &ldquo;gummi&rdquo; candies) should be sought prior to the administration of any gelatin-containing vaccine (",
"    <a class=\"graphic graphic_table graphicRef63833 \" href=\"mobipreview.htm?32/7/32891\">",
"     table 4",
"    </a>",
"    ). However, a negative history to the ingestion of gelatin does not definitively exclude an allergic reaction to gelatin injected with the vaccine, and patients who have experienced a reaction to a vaccine may require testing for gelatin allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Skin testing with vaccines and vaccine constituents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Persons who react to gelatin on ingestion should be evaluated by an allergist prior to vaccine administration. If the history is consistent with an immediate-type allergic reaction to gelatin and this is confirmed by skin tests or serum specific IgE antibody tests to gelatin, it is prudent to skin test such patients with gelatin-containing vaccines prior to administration. If the vaccine skin tests are negative, the vaccine can be given in the usual manner but the patient observed for at least 30 minutes afterward. If the vaccine skin tests are positive, the vaccine can be administered in graded doses.",
"   </p>",
"   <p>",
"    The incidence of allergic reactions to gelatin in vaccines was particularly high in Japan, a phenomenon that was subsequently attributed, in part, to genetic characteristics of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Japanese manufacturers removed gelatin from some vaccines and switched to a more thoroughly hydrolyzed gelatin in others, with a dramatic reduction in the rate of reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/24\">",
"     24",
"    </a>",
"    ]. These strategies have been variably adopted in other countries and reactions to gelatin in vaccines still occur (",
"    <a class=\"graphic graphic_table graphicRef63833 \" href=\"mobipreview.htm?32/7/32891\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Egg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg protein is present in yellow fever, influenza,",
"    <span class=\"nowrap\">",
"     measles/mumps/rubella,",
"    </span>",
"    and some rabies vaccines, although the amounts are clinically significant only in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef51011 \" href=\"mobipreview.htm?19/45/20187\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3417929\">",
"     'Sources of information'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of allergy after the ingestion of egg, raw or cooked, should be sought prior to the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"       yellow fever vaccine",
"      </a>",
"      , and persons with positive histories should be evaluated by an allergist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/26\">",
"       26",
"      </a>",
"      ]. Such patients should be skin tested with yellow fever vaccine prior to administration. If the vaccine skin tests are negative, the vaccine can be given in the usual manner but the patient observed for at least 30 minutes afterward. If the vaccine skin tests are positive, the vaccine can be administered in graded doses. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Skin testing with vaccines and vaccine constituents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The recommendations regarding the administration of influenza vaccines to persons allergic to egg are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"       \"Influenza vaccination in individuals with egg allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Measles/mumps/rubella",
"      </span>",
"      and rabies vaccines may be safely administered in the usual manner to patients with egg allergy (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Measles, mumps, and rubella'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chicken",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chicken proteins may also be present in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    and may be responsible for reactions in chicken-allergic recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3417929\">",
"     'Sources of information'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832795\">",
"    <span class=\"h2\">",
"     Cow&rsquo;s milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Casein, an allergenic protein contained in cow&rsquo;s milk, has been preliminarily implicated in causing anaphylaxis to diphtheria, tetanus, and pertussis vaccines (DTaP or Tdap) in a small number of severely milk-allergic children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/28\">",
"     28",
"    </a>",
"    ]. The vaccines are prepared in a medium derived from cow&rsquo;s milk protein and nanogram quantities of residual casein have been demonstrated in these preparations. However, the vast majority of even severely milk-allergic patients have no allergic reactions to these vaccines. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Tetanus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thimerosal, aluminum, and phenoxyethanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thimerosal, aluminum, and phenoxyethanol are added to some vaccines as preservatives, although the use of thimerosal (which contains mercury) in vaccines is decreasing with time, due to concerns about cumulative mercury exposure in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=see_link&amp;anchor=H5#H5\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\", section on 'Mercury toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19418?source=see_link&amp;anchor=H8#H8\">",
"     \"Standard childhood vaccines: Parental hesitancy or refusal\", section on 'Why parents refuse vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These preservatives have not been documented to cause immediate-type allergic reactions to vaccines and immediate-type skin testing is not generally indicated. However, they can cause delayed-type hypersensitivity reactions and contact dermatitis when applied topically to the skin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contact sensitivity to them is not a contraindication to receiving vaccines containing them [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5,29-31\">",
"       5,29-31",
"      </a>",
"      ]. There is a case report of an adult who developed a generalized maculopapular rash to a thimerosal-containing influenza vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/32\">",
"       32",
"      </a>",
"      ]; this was thought to be a T cell-mediated allergic response to thimerosal because of a positive patch test to this substance. This is a rare and unpredictable complication, if indeed there is actually a causal relationship.",
"     </li>",
"     <li>",
"      The ability of these agents to cause delayed local reactions after vaccination is another concern, for which some limited evidence exists. One study examined 125 patients with patch-test positive contact sensitivity to thimerosal or its derivatives, who were challenged with intramuscular injections of thimerosal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/33\">",
"       33",
"      </a>",
"      ]. Only 4 percent (five patients) developed mild local reactions to the injection, indicating that local reactions are uncommon even in these contact-sensitized patients.",
"     </li>",
"     <li>",
"      Rarely, aluminum-containing vaccines cause persistent nodules at the injection site, possibly because of delayed hypersensitivity or other immune responses to aluminum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patch testing or any specific testing for suspected sensitivity to these preservatives for the purpose of assessing a patient's ability to tolerate a vaccine containing it is not necessary. Patch testing can be performed for the diagnosis of allergic contact dermatitis, but this is not helpful in relation to vaccination. If a patient with documented contact dermatitis to one of these additives is concerned about receiving a vaccine containing the same agent, then it is prudent to administer a formulation that does not contain it, if available. Similarly, if a patient with known contact sensitivity has had a bothersome local reaction to a vaccine containing the preservative in the past and needs another, it would be prudent to give a product that is free of that preservative, if available. (See",
"    <a class=\"local\" href=\"#H3417929\">",
"     'Sources of information'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antimicrobials may be added in trace amounts to vaccines, most commonly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . Although there are no specific reports of vaccine-induced anaphylaxis in which these drugs were found to be the cause, the rare patients who have experienced anaphylactic reactions confirmed to be due to these antibiotics should not receive vaccines containing them. (See",
"    <a class=\"local\" href=\"#H3417929\">",
"     'Sources of information'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, contact dermatitis to these antimicrobials is not a contraindication to administration of vaccines containing trace amounts of them; immediate reactions in this clinical setting have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Latex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"rubber\" in vaccine vial stoppers or syringe plungers may be either dry natural rubber (DNR) latex or synthetic rubber. Those made with latex pose a theoretical risk to latex-allergic patients, either as a result of liquid vaccine solution extracting latex allergens from the stopper by physical contact, or by passing the needle through the stopper and retaining latex allergen in or on the needle. One report of an anaphylactic reaction after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    administered to a latex-allergic patient was attributed to rubber in the stopper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/34\">",
"     34",
"    </a>",
"    ]. A review of &gt;160,000 reports from the Vaccine Adverse Event Reporting System (VAERS) found only 28 cases of possible immediate-type allergic reactions after receiving a DNR-containing vaccine and these may have been due to other components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/35\">",
"     35",
"    </a>",
"    ]. The latex content of vaccine packaging can be found at",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf\">",
"     www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients with anaphylaxis to latex can safely receive vaccines from vials with non-DNR stoppers. If the only available preparation has a latex stopper, the stopper should be removed and the vaccine drawn up directly from the vial without passing the needle through the stopper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/36\">",
"     36",
"    </a>",
"    ]. If the only available vaccine contains latex in the packaging that cannot be avoided, such as in a prefilled syringe, the vaccine can still be administered but the patient should be observed for at least 30 minutes afterward.",
"   </p>",
"   <p>",
"    In contrast to patients with latex-induced anaphylaxis, patients with contact allergy to latex (such as hand dermatitis) may safely receive vaccines from vials with latex stoppers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Yeast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B and human papillomavirus vaccines contain yeast protein, but adverse reactions to these, if any, appear to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/37\">",
"     37",
"    </a>",
"    ]. Yeast allergy itself is very rare but, if a patient has a history of clinical reactivity to Baker's or Brewer&rsquo;s yeast and a positive skin test to",
"    <em>",
"     Saccharomyces cerevisiae",
"    </em>",
"    , it would be appropriate to skin test with yeast-containing vaccines prior to administration. If the vaccine skin tests are negative, the vaccine can be given in the usual manner but the patient observed for at least 30 minutes afterward. If the vaccine skin tests are positive, the vaccine can be administered in graded doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dextran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     Dextran",
"    </a>",
"    has been implicated in allergic reactions to a particular brand of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/0/14343?source=see_link\">",
"     measles-mumps-rubella vaccine",
"    </a>",
"    previously used in Italy and Brazil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/38\">",
"     38",
"    </a>",
"    ]. The reactions were related to the presence of IgG antibodies to dextran and the mechanism was hypothesized to be complement activation and anaphylatoxin release. This brand of vaccine has been withdrawn from the market, although dextran is found sporadically in other vaccines, (eg, some rotavirus vaccines).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IgE-MEDIATED REACTIONS TO SPECIFIC VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature contains various reports of IgE-mediated reactions to specific vaccines, as summarized in this section. Rarely, these involve anaphylactic reactions to the microbial components of the vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diphtheria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a report of anaphylaxis after a DT booster with skin tests and RAST positive to both diphtheria and tetanus toxoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/39\">",
"     39",
"    </a>",
"    ]. Generalized hives attributed to IgE directed against the diphtheria component of \"Di-Te-Pol\" (diphtheria-tetanus-polio) vaccine are also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/40\">",
"     40",
"    </a>",
"    ]. Children with reactions to DT vaccines sometimes lose the hypersensitivity with time, so a childhood reaction to this vaccine does not necessarily preclude its future use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports consistent with anaphylaxis to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , but none have been confirmed with skin tests or measurement of allergen-specific IgE in serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/42\">",
"     42",
"    </a>",
"    ]. Reviews of the literature on adverse reactions to hepatitis B vaccination suggest that the rate of anaphylaxis is less than 1 in 100,000 vaccinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Haemophilus influenza type b",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports consistent with anaphylaxis to Haemophilus influenza type b (Hib) vaccine, but none have been confirmed with skin tests or measurement of allergen-specific IgE in serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/42\">",
"     42",
"    </a>",
"    ]. There is a case of anaphylaxis after Haemophilus influenza type b (Hib)-conjugate vaccine demonstrated to be due to the diphtheria conjugating protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/44\">",
"     44",
"    </a>",
"    ]. This report demonstrates the importance of determining the specific culprit allergen since other vaccines contain the same conjugating protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Human papillomavirus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis following administration of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/35/43574?source=see_link\">",
"     human papillomavirus vaccine",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In most cases, this occurred after the initial dose of this vaccine, although a few patients developed symptoms after the second dose. Gardasil contains trace yeast proteins and the stabilizer polysorbate 80. However, four patients who had apparent anaphylactic reactions to it were skin test-negative to the vaccine, baker's yeast, and polysorbate 80. Vaccination in adolescents is associated with a high rate of syncope, which may account for some of the events diagnosed as anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influenza vaccine contains egg protein, as previously discussed, although not all reactions to it are due to egg. Reactions to the influenza vaccine are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link&amp;anchor=H3#H3\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Risk of anaphylaxis to vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Japanese encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some immediate type anaphylactic reactions have been reported with the Japanese encephalitis (JE) vaccine, including some reactions in which patients had IgE antibodies to gelatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/20\">",
"     20",
"    </a>",
"    ]. With this vaccine in particular, there have been many reports of",
"    <strong>",
"     late-onset",
"    </strong>",
"    anaphylaxis (many hours to two weeks after vaccination) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/48\">",
"     48",
"    </a>",
"    ]. A new Japanese encephalitis vaccine does not contain gelatin; whether or not this vaccine will have a lower rate of adverse reactions has yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most anaphylactic reactions to MMR are due to gelatin allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/18\">",
"     18",
"    </a>",
"    ]. There is no relation to egg allergy since the vaccine contains no, or a minuscule amount of, egg protein. The safety of administering MMR vaccine to people with egg allergy was demonstrated in a study of 54 children who had never been vaccinated, but had confirmed egg allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/49\">",
"     49",
"    </a>",
"    ]. Skin testing was performed with the vaccine in 17 children, and 3 were positive. All the children were given the MMR vaccine as a single full dose and none had immediate or delayed adverse reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Meningococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions to meningococcal polysaccharide or polysaccharide-protein conjugate vaccines are very rare, one per million doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pneumococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two reports of anaphylaxis in children who received 23-valent pneumococcal vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. IgE antibody to the vaccine was demonstrated by skin tests or measurement of allergen-specific IgE in serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports consistent with anaphylaxis, but none confirmed with skin tests or measurement of allergen-specific IgE in serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/53\">",
"     53",
"    </a>",
"    ]. Some late-onset (several days after vaccination) serum sickness-like reactions and urticaria associated with IgE antibodies to betapropiolactone-altered human serum albumin in the vaccine have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports consistent with anaphylaxis (including fatalities) to tetanus vaccines, some of which were supported by positive skin tests and elevated levels of allergen-specific IgE directed against the tetanus and diphtheria toxoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/39,42,55,56\">",
"     39,42,55,56",
"    </a>",
"    ]. However, children with reactions to DT vaccines sometimes lose the hypersensitivity with time, so a childhood reaction to this vaccine does not necessarily preclude its future use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/41\">",
"     41",
"    </a>",
"    ]. Diphtheria, tetanus, and pertussis vaccines (DTaP or Tdap) may also contain trace (nanogram) quantities of residual casein (an allergenic milk protein) from the milk-based medium in which they are produced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility that this residual casein could be responsible for some anaphylactic reactions to the vaccines was raised by a case series of eight children who developed anaphylaxis within one hour (6 within 20 minutes) of receiving DTaP or Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/28\">",
"     28",
"    </a>",
"    ]. Six had histories of past allergic reactions to cow&rsquo;s milk and two had elevated specific IgE levels to milk in serum in the setting of atopic dermatitis or proctocolitis, leading to removal of milk from the diet. All had markedly elevated levels of milk specific serum IgE (59 to &gt;100",
"    <span class=\"nowrap\">",
"     kIU/L)",
"    </span>",
"    prior to vaccination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=see_link\">",
"     \"Milk allergy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of this report require confirmation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/57\">",
"     57",
"    </a>",
"    ]. Most patients, even those with severe cow&rsquo;s milk allergy, tolerate the vaccines as evidenced by the observations that milk allergy is common in infants and anaphylaxis to these vaccines is rare. Until more information is available, we suggest that infants with severe milk allergy be observed for at least 30 minutes after vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Typhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are several reports of severe reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    within one hour of vaccination, the reports are not consistent with anaphylaxis, but rather involve high fever, vomiting, and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of anaphylaxis is reported to be three reactions per million doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/59\">",
"     59",
"    </a>",
"    ]. Most anaphylactic reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    are due to gelatin allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Yellow fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many reports consistent with anaphylaxis to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/60\">",
"     60",
"    </a>",
"    ]. The constituent responsible for these apparently IgE-mediated reactions has not been investigated, but the vaccine contains gelatin as well as egg and chicken proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH SUSPECTED VACCINE ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach described in this section is consistent with published practice guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef81252 \" href=\"mobipreview.htm?15/19/15668\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/61\">",
"     61",
"    </a>",
"    ]. Of note, this algorithm applies to patients with a history of a suspected allergic reaction",
"    <strong>",
"     to a vaccine",
"    </strong>",
"    . In contrast, the diagnostic approach is different for a patient who has reacted to a",
"    <strong>",
"     vaccine constituent",
"    </strong>",
"    such as gelatin, egg, latex, or yeast, but not to vaccination itself. The most commonly encountered example of this situation is influenza vaccination of a patient with egg allergy, which is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Are the nature and timing of reaction consistent with anaphylaxis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to determine if the nature and timing of the reaction are consistent with an IgE-mediated",
"    <span class=\"nowrap\">",
"     reaction/anaphylaxis",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Is there a history of a similar reaction?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It also extremely important to obtain a possible history of similar reactions to the same or other vaccines, or to vaccine constituents. The various components of a vaccine are clearly listed in the package inserts supplied by the manufacturers.",
"   </p>",
"   <p>",
"    If the reaction occurred with the first dose of a vaccine, the chance that the immunizing agent itself is the allergen is greatly diminished. In this clinical situation, healthcare professionals should also inquire about allergic reactions to food, particularly gelatin (",
"    <a class=\"graphic graphic_table graphicRef63833 \" href=\"mobipreview.htm?32/7/32891\">",
"     table 4",
"    </a>",
"    ) and egg (",
"    <a class=\"graphic graphic_table graphicRef51011 \" href=\"mobipreview.htm?19/45/20187\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Is there a need for future doses of this vaccine or other vaccines with common components?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a history has been obtained of a vaccine reaction occurring shortly after administration that is",
"    <strong>",
"     consistent",
"    </strong>",
"    with an IgE-mediated reaction, the clinician should determine if future doses of the suspect vaccine, or other vaccines with common components, are required. Given the potential for cross-reaction with common components in other vaccines and with foods, a thorough evaluation is appropriate, even if no further doses of the suspect vaccine are required.",
"   </p>",
"   <p>",
"    Since many vaccines are given as a series, some recipients generate an adequate response to fewer than the usual number of doses. Thus, it is reasonable to determine the antibody level achieved by the doses already received. Protective levels of specific antibody have been determined for many vaccines and some are routinely available in commercial reference laboratories. If a patient has already mounted a sufficient antibody response, consideration can be given to not giving further doses of the vaccine. However, the level of protective antibody may not persist as long in persons vaccinated with fewer than the usual number of doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SKIN TESTING WITH VACCINES AND VACCINE CONSTITUENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient must receive further doses of a vaccine, skin testing with the vaccine should be performed. Proper performance and interpretation of skin tests requires expertise in the procedure, including the use of appropriate positive and negative controls. Also, skin tests themselves can rarely cause anaphylactic reactions in highly allergic individuals. Thus, skin testing should only be performed by persons such as allergists with training in interpretation of, and treatment of possible reactions to, the tests, and only in a setting where anaphylactic reactions can be recognized and treated quickly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaccine should first be tested by the skin prick method. Full-strength vaccine can be used, unless the history of reaction was truly life-threatening, in which case it is appropriate to dilute the vaccine before skin prick testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the full-strength prick test is negative, an intradermal test with the vaccine diluted 1:100 in 0.9 percent (isotonic) saline should be performed, again with appropriate positive and negative controls. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Irritant reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Interpreting skin tests to vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of the reaction is critically important in interpreting skin tests to vaccines. Clinically irrelevant positive skin tests are possible, as with skin testing to any allergen. The presence of a positive skin test to a vaccine is not necessarily predictive of a subsequent reaction, although it must be viewed as a significant risk factor.",
"   </p>",
"   <p>",
"    Vaccines can induce IgE antibody production in the days to weeks after vaccination, although the clinical significance of this is unclear. Specific IgE to diphtheria and tetanus toxoids was induced by vaccination and found to persist for at least two years after immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This specific IgE was not associated with allergic reactions with subsequent vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Irritant reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant (false-positive) skin test reactions are also possible, particularly with intradermal testing at concentrations of 1:10 or undiluted. One study of 20 adult volunteers without histories of vaccine reactions evaluated responses to skin prick testing and intradermal testing with 10 common vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/64\">",
"     64",
"    </a>",
"    ]. Irritant reactions were not seen with skin prick testing and were uncommon after intradermal testing with a 1:100 concentration. However, they were common at higher intradermal concentrations (1:10 or undiluted), particularly with influenza, MMR, and varicella vaccines. Thus, intradermal testing to undiluted preparations of these three vaccines appears to be of little value and results of intradermal tests at the 1:10 concentration are of uncertain value. At the 1:100 concentration, rates of irritant reactions were 5 percent for DT and DTaP, and 15 percent for influenza.",
"   </p>",
"   <p>",
"    If a patient with a suspected IgE-mediated reaction to a vaccine is skin-test positive, the same dilution of the vaccine should also be placed on several volunteer control individuals, preferably those who have previously received the vaccine uneventfully. If these controls also have positive skin tests, the patient's positive skin test is less likely to be clinically relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Delayed reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed type hypersensitivity reactions at the site of skin testing with a vaccine have been observed. These reactions are not relevant to the diagnosis of IgE-mediated vaccine allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Testing for vaccine constituents",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the suspect vaccine contains egg (yellow fever and influenza) (",
"    <a class=\"graphic graphic_table graphicRef51011 \" href=\"mobipreview.htm?19/45/20187\">",
"     table 5",
"    </a>",
"    ), gelatin proteins (",
"    <a class=\"graphic graphic_table graphicRef63833 \" href=\"mobipreview.htm?32/7/32891\">",
"     table 4",
"    </a>",
"    ), latex (",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/pink-appendx.htm\">",
"     www.cdc.gov/vaccines/pubs/pinkbook/pink-appendx.htm",
"    </a>",
"    ) or",
"    <em>",
"     Saccharomyces cerevisiae",
"    </em>",
"    yeast (hepatitis B and human papillomavirus) the patient should also be skin tested to these constituents:",
"   </p>",
"   <p>",
"    Skin prick testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Egg and Saccharomyces cerevisiae yeast extracts for skin testing are commercially available.",
"     </li>",
"     <li>",
"      Gelatin extract can be prepared by dissolving one teaspoon of sugared gelatin powder of any color or flavor (for example Jell-O&reg;) in 5 mL of normal saline to create a prick skin test solution.",
"     </li>",
"     <li>",
"      Standardized extracts of natural rubber latex (NRL) for skin testing are commercially available in many countries, although not in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of allergen-specific IgE in serum:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific IgE to egg, gelatin, latex, and yeast can be measured in serum by using commercially-available immunoassays. The sensitivity of the latex ImmunoCAP",
"      <sup>",
"       &reg;",
"      </sup>",
"      and Immulite",
"      <sup>",
"       &reg;",
"      </sup>",
"      assays is approximately 80 percent, as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link&amp;anchor=H20#H20\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Serology testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     ADMINISTRATION OF VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     General strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the intradermal test with the vaccine is negative, the chance that the patient has IgE antibody to any vaccine constituent is negligible, and the vaccine can be administered in the usual manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Nonetheless, it is prudent to observe such patients for at least 30 minutes after administration, with epinephrine and other treatment available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If vaccine or vaccine component skin tests are positive, alternatives to vaccination should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/67\">",
"     67",
"    </a>",
"    ]. However, if deemed necessary, the vaccine may still be administered, using a graded dose protocol. A graded protocol is provided in the footnote 2 of the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef81252 \" href=\"mobipreview.htm?15/19/15668\">",
"     algorithm 1",
"    </a>",
"    ). Successful administration of vaccines to patients with positive skin tests using graded protocols has been described for several different vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/5/43097/abstract/27,55,68\">",
"     27,55,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of a vaccine to an allergic person, even by such a graded dose protocol, still carries the risk of an anaphylactic reaction and should be undertaken",
"    <strong>",
"     only after",
"    </strong>",
"    obtaining written informed consent and ensuring that a written emergency protocol is in place for the recognition and treatment of anaphylaxis and that the appropriate medications and supplies are available; also that personnel are trained to recognize and to treat anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Giving influenza vaccine to an egg-allergic patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of influenza vaccine to an egg-allergic patient is a relatively common clinical dilemma. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link&amp;anchor=H12#H12\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Administration protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       \"Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylactic reactions to vaccines are rare, although potentially life-threatening. These IgE-mediated reactions are most often due to vaccine constituents rather than microbial products.",
"     </li>",
"     <li>",
"      Symptoms of anaphylactic reactions to vaccines are similar to those of anaphylaxis from other etiologies (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ). They usually appear within 5 to 30 minutes, but may be delayed up to several hours. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been reports of systemic allergic reactions to nearly every vaccine, although some vaccines are more commonly implicated, including the vaccines for yellow fever, MMR, and tetanus. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'IgE-mediated reactions to specific vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of a possible vaccine allergy begins with determining if symptoms and timing are consistent with an anaphylactic reaction (",
"      <a class=\"graphic graphic_algorithm graphicRef81252 \" href=\"mobipreview.htm?15/19/15668\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ). The next step is discerning if the patient had previous exposure to the vaccine or needs further doses of the vaccine in question, or similar vaccines, in the future. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Approach to the patient with suspected vaccine allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing to vaccines should be performed and interpreted by an allergy specialist. The skin prick test may be performed with an undiluted solution of the vaccine in question, or with a diluted solution in patients whose reactions were truly life-threatening. If negative, this is followed by intradermal testing with a 1:100 dilution of the vaccine. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Skin testing with vaccines and vaccine constituents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the suspect vaccine contains egg (influenza and yellow fever), gelatin (",
"      <a class=\"graphic graphic_table graphicRef63833 \" href=\"mobipreview.htm?32/7/32891\">",
"       table 4",
"      </a>",
"      ), latex (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf\">",
"       www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf",
"      </a>",
"      HYPERLINK) or",
"      <em>",
"       Saccharomyces cerevisiae",
"      </em>",
"      yeast (hepatitis B and human papillomavirus), skin testing to these constituents should also be performed. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Skin testing with vaccines and vaccine constituents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If skin testing with the vaccine is negative, it is recommended that the patient receive the vaccine in the usual manner. For safety, such patients are usually given the vaccine under the supervision of the allergy specialist. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Administration of vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If skin testing to a constituent (gelatin, egg, etc) or the vaccine is positive, it may still be possible for the patient to receive the vaccine in a graded manner (",
"      <a class=\"graphic graphic_algorithm graphicRef81252 \" href=\"mobipreview.htm?15/19/15668\">",
"       algorithm 1",
"      </a>",
"      ). However, this should only be undertaken after a thorough assessment of the relative risks and benefits of vaccination. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Administration of vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/1\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/2\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/3\">",
"      Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/4\">",
"      Patja A, M&auml;kinen-Kiljunen S, Davidkin I, et al. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001; 107:E27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/5\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/6\">",
"      Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/7\">",
"      Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/8\">",
"      Talbot EA, Brown KH, Kirkland KB, et al. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010; 28:8001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/9\">",
"      Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009; 5:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/11\">",
"      Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM. Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis 2009; 49:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/12\">",
"      Vessal S, Kravis LP. Immunologic mechanisms responsible for adverse reactions to routine immunizations in children. Clin Pediatr (Phila) 1976; 15:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/13\">",
"      Froehlich H, Verma R. Arthus reaction to recombinant hepatitis B virus vaccine. Clin Infect Dis 2001; 33:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/14\">",
"      Rogerson SJ, Nye FJ. Hepatitis B vaccine associated with erythema nodosum and polyarthritis. BMJ 1990; 301:345.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman PL. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy principles and practice, 6th ed, Adkinson NF Jr, Busse WW, Yunginger JW, et al (Eds), Elsevier, St. Louis 2003. p.1497.",
"    </li>",
"    <li>",
"     The Institute for Vaccine Safety. www.vaccinesafety.edu (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/17\">",
"      Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993; 91:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/18\">",
"      Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/19\">",
"      Sakaguchi M, Yamanaka T, Ikeda K, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol 1997; 99:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/20\">",
"      Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001; 56:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/21\">",
"      Lasley MV. Anaphylaxis after booster influenza vaccine due to gelatin allergy. Pediatr Asthma Allergy Immunol 2007; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/22\">",
"      Kumagai T, Yamanaka T, Wataya Y, et al. A strong association between HLA-DR9 and gelatin allergy in the Japanese population. Vaccine 2001; 19:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/23\">",
"      Sakaguchi M, Nakayama T, Kaku H, et al. Analysis of HLA in children with gelatin allergy. Tissue Antigens 2002; 59:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/24\">",
"      Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007; 25:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/25\">",
"      O'Brien TC, Maloney CJ, Tauraso NM. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. Appl Microbiol 1971; 21:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/26\">",
"      Kelso JM. Raw egg allergy-a potential issue in vaccine allergy. J Allergy Clin Immunol 2000; 106:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/27\">",
"      Kelso JM, Cockrell GE, Helm RM, Burks AW. Common allergens in avian meats. J Allergy Clin Immunol 1999; 104:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/28\">",
"      Kattan JD, Konstantinou GN, Cox AL, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol 2011; 128:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/29\">",
"      Grabenstein JD. Clinical management of hypersensitivities to vaccine components. Hosp Pharm 1997; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/30\">",
"      Heidary N, Cohen DE. Hypersensitivity reactions to vaccine components. Dermatitis 2005; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/31\">",
"      Patrizi A, Rizzoli L, Vincenzi C, et al. Sensitization to thimerosal in atopic children. Contact Dermatitis 1999; 40:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/32\">",
"      Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy Asthma Immunol 2005; 94:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/33\">",
"      Audicana MT, Mu&ntilde;oz D, del Pozo MD, et al. Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat 2002; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/34\">",
"      Lear JT, English JS. Anaphylaxis after hepatitis B vaccination. Lancet 1995; 345:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/35\">",
"      Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/36\">",
"      Hamilton RG, Brown RH, Veltri MA, et al. Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures. Am J Health Syst Pharm 2005; 62:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/37\">",
"      DiMiceli L, Pool V, Kelso JM, et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/38\">",
"      Zanoni G, Puccetti A, Dolcino M, et al. Dextran-specific IgG response in hypersensitivity reactions to measles-mumps-rubella vaccine. J Allergy Clin Immunol 2008; 122:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/39\">",
"      Mart&iacute;n-Mu&ntilde;oz MF, Pereira MJ, Posadas S, et al. Anaphylactic reaction to diphtheria-tetanus vaccine in a child: specific IgE/IgG determinations and cross-reactivity studies. Vaccine 2002; 20:3409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/40\">",
"      Skov PS, Pelck I, Ebbesen F, Poulsen LK. Hypersensitivity to the diphtheria component in the Di-Te-Pol vaccine. A type I allergic reaction demonstrated by basophil histamine release. Pediatr Allergy Immunol 1997; 8:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/41\">",
"      B&eacute;gin P, Vu MQ, Picard M, et al. Spontaneous resolution of diphtheria-tetanus vaccine hypersensitivity in a pediatric population. Allergy 2011; 66:1508.",
"     </a>",
"    </li>",
"    <li>",
"     Adverse events associated with childhood vaccines: Evidence bearing on causality, Stratton KR, Howe CJ, Johnston RB (Eds), National Academy Press, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/43\">",
"      Systemic adverse effects of hepatitis B vaccines are rare. Prescrire Int 2004; 13:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/44\">",
"      Nelson MR, Oaks H, Smith LJ, et al. Anaphylaxis complicating routine childhood immunization: Hemophilus Influenza b conjugated vaccine. Pediatr Asthma Allergy Immunol 2000; 14:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/45\">",
"      Brotherton JM, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/46\">",
"      Kang LW, Crawford N, Tang ML, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008; 337:a2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/48\">",
"      Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000; 18:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/49\">",
"      James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/50\">",
"      Ball R, Braun MM, Mootrey GT, Vaccine Adverse Event Reporting System Working Group. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis 2001; 32:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/51\">",
"      Ponvert C, Ardelean-Jaby D, Colin-Gorski AM, et al. Anaphylaxis to the 23-valent pneumococcal vaccine in child: a case-control study based on immediate responses in skin tests and specific IgE determination. Vaccine 2001; 19:4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/52\">",
"      Ponvert C, Scheinmann P, de Blic J. Anaphylaxis to the 23-valent pneumococcal vaccine: a second explored case by means of immediate-reading skin tests with pneumococcal vaccines. Vaccine 2010; 28:8256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/53\">",
"      Centers for Disease Control (CDC). Systemic allergic reactions following immunization with human diploid cell rabies vaccine. MMWR Morb Mortal Wkly Rep 1984; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/54\">",
"      Swanson MC, Rosanoff E, Gurwith M, et al. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 1987; 155:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/55\">",
"      Carey AB, Meltzer EO. Diagnosis and \"desensitization\" in tetanus vaccine hypersensitivity. Ann Allergy 1992; 69:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/56\">",
"      Mayorga C, Torres MJ, Corzo JL, et al. Immediate allergy to tetanus toxoid vaccine: determination of immunoglobulin E and immunoglobulin G antibodies to allergenic proteins. Ann Allergy Asthma Immunol 2003; 90:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/57\">",
"      Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. J Allergy Clin Immunol 2011; 128:434; author reply 435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/58\">",
"      Hoyt RE, Herip DS. Severe systemic reactions attributed to the acetone-inactivated parenteral typhoid vaccine. Mil Med 1996; 161:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/59\">",
"      Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/60\">",
"      Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999; 103:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/61\">",
"      Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/62\">",
"      Mark A, Bj&ouml;rkst&eacute;n B, Granstr&ouml;m M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995; 13:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/63\">",
"      Aalberse RC, van Ree R, Danneman A, Wahn U. IgE antibodies to tetanus toxoid in relation to atopy. Int Arch Allergy Immunol 1995; 107:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/64\">",
"      Wood RA, Setse R, Halsey N, Clinical Immunization Safety Assessment (CISA) Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol 2007; 120:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/65\">",
"      Bierman CW, Shapiro GG, Pierson WE, et al. Safety of influenza vaccination in allergic children. J Infect Dis 1977; 136 Suppl:S652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/66\">",
"      Miller JR, Orgel HA, Meltzer EO. The safety of egg-containing vaccines for egg-allergic patients. J Allergy Clin Immunol 1983; 71:568.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/5/43097/abstract/68\">",
"      Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985; 106:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2074 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-877DD6BC00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43097=[""].join("\n");
var outline_f42_5_43097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4744788\">",
"      Immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Definition of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Delayed vaccine reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4744967\">",
"      Vasovagal reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REACTIONS TO VACCINE CONSTITUENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3417929\">",
"      Sources of information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gelatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chicken",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H832795\">",
"      Cow&rsquo;s milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thimerosal, aluminum, and phenoxyethanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Latex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dextran",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IgE-MEDIATED REACTIONS TO SPECIFIC VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diphtheria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Haemophilus influenza type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Human papillomavirus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Japanese encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Measles, mumps, and rubella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Meningococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pneumococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rabies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Typhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Yellow fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      APPROACH TO THE PATIENT WITH SUSPECTED VACCINE ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Are the nature and timing of reaction consistent with anaphylaxis?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Is there a history of a similar reaction?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Is there a need for future doses of this vaccine or other vaccines with common components?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SKIN TESTING WITH VACCINES AND VACCINE CONSTITUENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Interpreting skin tests to vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Irritant reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Delayed reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Testing for vaccine constituents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      ADMINISTRATION OF VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      General strategy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Giving influenza vaccine to an egg-allergic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2074|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?15/19/15668\" title=\"algorithm 1\">",
"      Approach allergic rxs vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 3\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/7/32891\" title=\"table 4\">",
"      Gelatin content of vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/45/20187\" title=\"table 5\">",
"      Egg content of vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19418?source=related_link\">",
"      Standard childhood vaccines: Parental hesitancy or refusal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_5_43098="Advanced case 12";
var content_f42_5_43098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1274px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Advanced case 12",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43098=[""].join("\n");
var outline_f42_5_43098=null;
var title_f42_5_43099="Incidence prostate CA pre PSA";
var content_f42_5_43099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of prostate cancer (adjusted for age)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Rates per 100,000 men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Increase, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1968-72",
"       </td>",
"       <td class=\"subtitle2\">",
"        1973-77&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New York State",
"       </td>",
"       <td>",
"        29.4",
"       </td>",
"       <td>",
"        39.9",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"        Detroit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        White men&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        36.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        41.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Black men",
"       </td>",
"       <td class=\"sublist_other\">",
"        67.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        73.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"        San Francisco Bay Area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        White men&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        44.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        47.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Black men",
"       </td>",
"       <td class=\"sublist_other\">",
"        77.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        92.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The age-adjusted incidence of prostate cancer between 1968 to 1972 and 1973 to 1977. There was a rising incidence of prostate cancer long before the widespread introduction of PSA-based screening practices.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Flanders, WD, Prostate 1984; 5:621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43099=[""].join("\n");
var outline_f42_5_43099=null;
var title_f42_5_43100="Sterilization processes";
var content_f42_5_43100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sterilization and disinfection processes and products for infection control, by device classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Device classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Devices (examples)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Spaulding process",
"classification/time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Processes",
"       </td>",
"       <td class=\"subtitle1\">",
"        EPA product classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Critical (enters sterile tissue or vascular system)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Implants, scalpels, needles, cardiac and urinary",
"catheters",
"       </td>",
"       <td>",
"        Sterilization",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purchase as sterile. Sterilize by steam under pressure. If heat labile use",
"ethylene oxide gas or chemical sterilants*",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Sterilant/disinfectant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Time:",
"        </strong>",
"        prolonged contact",
"(hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Semi-critical (touches intact mucous membranes [except dental])",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Flexible endoscopes",
"laryngoscopes endotracheal tubes, cervical diaphragms",
"       </td>",
"       <td>",
"        High-level disinfection",
"- destroys all micro-organisms except high numbers of bacterial spores",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Wet pasteurization or",
"chemical disinfectants&bull;. Heat sterilization preferred for between",
"patient processing of heat stable instruments. Follow by rinsing with",
"sterile water.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Sterilant/disinfectant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Time:",
"        </strong>",
"        20 minutes or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Thermometers hydrotherapy tanks",
"       </td>",
"       <td>",
"        Intermediate-level disinfection - inactivates tubercle",
"bacilli, vegetative bacteria, most viruses and fungi. Does not",
"necessarily kill bacterial spores.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chemical disinfectants; sodium hypochlorite ethyl or",
"isopropyl alcohol, phenolic and iodophor solutions",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hospital disinfectant with label claim for",
"tuberculocidal activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Time:",
"        </strong>",
"        10 minutes or less",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Noncritical (touches intact skin, not mucous membranes)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Stethoscopes, bedpans,",
"blood pressure cuffs, patient furniture",
"       </td>",
"       <td>",
"        Low-level disinfection",
"-&nbsp;kills most bacteria, some viruses and fungi. Cannot reliably",
"kill resistant micororganisms (eg, tubercle bacilli, bacterial spores).",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chemical disinfectants;",
"ethyl or isopropyl alcohol, sodium hypochlorite, iodophor solution,",
"quarternary ammonium germicidal detergent",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hospital disinfectant",
"without label claim for tuberculocidal activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Time:",
"        </strong>",
"        10 minutes or less",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    EPA: Environmental Protection Agency",
"    <div class=\"footnotes\">",
"     * 2 percent glutaraldehyde-based products, 6 percent stabilized hydrogen peroxide, peracetic acid.",
"     <br>",
"      &bull; 2 percent glutaraldehyde-based products, 6 percent stabilized hydrogen peroxide, chlorine, peracetic acid.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rutala WA. APIC guideline for selection and use of disinfectants. Am J Infect Control 1996; 24:313. Copyright &copy; 1996 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43100=[""].join("\n");
var outline_f42_5_43100=null;
var title_f42_5_43101="Motivational interviewing technique - Engaging";
var content_f42_5_43101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F87241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F87241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motivational interviewing technique - Engaging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-motivational interviewing (MI) approach: Engaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The first vignette illustrates a routine clinic visit that is unlikely to lead to change, or worse, may further demoralize the patient. MI-inconsistent techniques are identified following the physician's statements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Hi Mrs. X, glad to see you today. How are you feeling?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, my asthma is acting up again. I might need a different medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Are you still smoking? (Closed question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes, but I'm cutting back.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         <strong>",
"          Doctor:",
"         </strong>",
"         You know that smoking aggravates your asthma and puts you at higher risk for other problems. (Providing information, overlooking change talk)",
"        </p>",
"        What have you tried to help you quit smoking? (Open question, possible premature focus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Oh, everything. It's so hard to quit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Well, I can write a prescription for one of the newer medications to help you quit. It's quite effective. (Providing information, likely premature focus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, okay&hellip;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In above vignette, the doctor rushes to a premature solution, and misses opportunities to elicit the patient's strengths and knowledge. By bypassing the processes of collaborative agenda setting and gathering more context for the patient's symptoms, the doctor fails to elicit or build the patient's motivation to change.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Motivational interviewing (MI) approach: Engaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compare the standard approach above to the following MI approach. MI-consistent techniques are identified following the physician's statements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Hi there Mrs. X, glad to see you today. How are you feeling?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, my asthma is acting up again. I might need a different medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         <strong>",
"          Doctor:",
"         </strong>",
"         You're thinking maybe a new medication would help. (Reflection) Let's put that on the list of possibilities. (Avoiding premature focus, agenda setting) First, let me listen to your breathing. Okay, I hear the trouble you're having. (Providing information)",
"        </p>",
"        <p>",
"         I'd like to spend about five minutes talking about your asthma broadly, before we decide together on the best approach to manage it. (Agenda setting, collaborative spirit)",
"        </p>",
"        How does that sound? (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        OK, that sounds good.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Tell me what concerns you most about your asthma. (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, it's really scary when I have an attack. I'm afraid I could die from this. But even on a regular day, I have less energy, and I feel older, due to it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So attacks make you worry you might die, and they are truly scary. (Reflection) But even on a daily basis, your life is diminished due to the asthma. (Complex reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Exactly. It's such a handicap! I wish I could get rid of it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        I bet you've thought about how you could lessen your symptoms and reduce the impact of asthma on your life. (Affirmation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes, I have. I think the first thing I should do is quit smoking.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You're clearly aware that smoking is making things worse, and you think you should quit. (Reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes, and I've already cut way back. I don't smoke in the house or car anymore, and I'm down to half a pack, where I was smoking a pack a day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You've already made a serious dent in the number of cigarettes per day. (Affirmation, reflection) How has that gone for you? (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, I made up my mind, and am keeping track of my smoking. I have a chart and I check off when I have a cigarette, and I stretch out the time between them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You're really taking it seriously. (Affirmation) You're already doing some of the things that experts recommend to make quitting work for you. (Providing information) What else have you thought about trying? (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, I heard there were some new medicines to help you quit. But I figured I have to be more ready. Can you tell me about the newer options?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You're not sure you're totally ready. (Reflection) I hear a lot of commitment from you in what you're already doing. (Reflection) Maybe considering a medication might be a next step to help you be even more ready. (Providing information) I'd be happy to review some of the information about the new medicines&hellip; (Providing information) &hellip;and then we can talk further about what the best next steps are for you.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43101=[""].join("\n");
var outline_f42_5_43101=null;
var title_f42_5_43102="Surfactant effect on lung pressure-volume";
var content_f42_5_43102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surfactant effect on lung pressure-volume in preterm rabbits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 304px; background-image: url(data:image/gif;base64,R0lGODlhrAEwAfcAAP///wAAAP+ZMwCZZu7u7iIiIpmZmYiIiN3d3RERETMzM2ZmZkRERHd3d7u7u8zMzP+zZqqqqhCfcP/mzfD59tDs4zCsg//MmVVVVWC/oKDZxkCzjBAQEMDm2f/584DMs/Dw8MDAwP+sWUBAQODg4AAmGf/Zs4CAgP+fQP/z5v/TpuDz7P/s2SCmef/GjQBfP2BgYDAwMP+5c/+mTf+/gLDf0AA5JqCgoFC5llBQUJDTvNDQ0AAJBgByTHDGqf/fwAAcE5CQkACPXwCFWSAgIABpRgB8UgBMMwATDHBwcLCwsAAvHxCCXA8JA1BZVhAsI39MGZCsowBWOWBzbN/GrUCMc++PL3CNg49vUM98KR8TBnCgj4BmTaCzrVB2aa+jllCvjzCifI98adDj3RCVaT85Mr+MWRBTPBCMYkBJRl85E++sXL+Zc3C8olCmiSB/X76+vjA5Nn9sWXCDfF9GLC8cCc+2nd+FLBBAMCBPP3Cpli98Se/CltDZ1mCsk+Dp5kCfgE8vD59fH7DWyTCZdqDPwFBsYzCPb++5dsDc0zCFaWBAILC5tm9CFj8mDJDJtu+VPAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACsATABAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27eHEaSBAgwAGBDvgmcJC3sOGYCAJEABAhwAMACf4eSHC4smWUiR8TCIDgQYCBji+LHv3RQAAGCgwAMFBgYIHFpGPLpoiggIMHGAoQYO16cYi+wIMLH068uPHjyJMrX868ufPn0KNLn069uvXrxW0eYODagGeBmx8n//w8uzxU8jQbE3YQgHBkAJMXojdPX+n8mQeA/wUQOMBg+fUFmNR9AwpoYFEEIpXggQzqtKBRDzYoIU0RElXhhHixR1hEBajGoYcbXSiUiBh+tUAAHibGnUgdStQiRyQCFWOJXC2QQGsANHDaSC9C1KNGM/oUJI1ZLYBBAhEQkMAC3LHXlwIE1NYAAAhElhgCiSnQ1wJatgcfcAsI9KORAnmGZZdhAtDii2t2yQAGfe23l38gCjQkTxFip+eefDI31wILbHcABtsVVMBfnkWgQJhXJjZlfn9xSVBmatZpZo4YAMAAd1WqtqaHazJAAHuZmjZqAQgwlgABBN25U56Xuf9q4gJKDlYoAifGKZBpCgjUKGf8kcebAwwAR9iPAChwgJKLeYlppdBC+6KXV+YXXKqgOQWrZbJ6BSgATMLHHQYKpMrAfo1BSSVnVwa7a2sJZAqAl8iyxtu8GzaQ6adieuohtZwd0CtC3eK0bWUF15imQIUqMOUDhwKQqAKZ/poqe+9utphpx9YJQK37bSpxAv4mO+VeJeO7LgLsqfbAwNk2dfBhCW/17UCF9qfAoVJSaSW7wGK8WmvWFtuxQSeySiWa/QYbgAIkRwtwqpNtWVDNNc1sGNZEisT1TFoX9nXXH40dU9gcIZsSAVrieJLZZMOorUJYE1BsXxiwqjZKB7j/vdC9DgFuENxd7zACCBkR7hLaE2GwogPlRstSAwv/7TdDgl8dd0cgxBAD4hcpzt8BDTQAW0mMS6SsQQXcveLLfU2Z45OPtd7XigPZ/eRuOPLGmmcF6GdtAGnOOVhw8/ZVwGN7dUkY8oNvzrnnoFdEOLHC7e0R2it04P334HtfQUG8LiC7mqImluR/VTpQaI7cte5znX1/zAAC9/r+HriVr/uAhvA5QObAVaqoSWqAMZPeRjr3OYvAjT2HegABdlOs/XiNbgf5wAA2yMEObnADB6Ec1FLFJgM4CTgGuJvyonUzwBCPVkN7VwwFcjPs9cV9uJthjviyo/y1BoF2UuD0/xpIEbhFoH8MO19I0KaBDTjxiVB0og8UsroSskdpAmGAEqOFgS0SAFCO8aEObxYvO+GQIPfqG2EKJUYgzkuIQwTdDkIAEbhh0SB3BEnqInIuwPynhEoKEwEw4L4EMC9MEXvAfwYSqI8hKQIJQIDdfui2b2lsNe0B4AEOAElWNaBXbOOOGDtJMDjGEQAwyEEdRRKBVrZyQyTZI0Sq5p/9lJA/bkpVrt5TAB5a8F14y+LtKMnINBXNS9YaDNv6ggAtJUABouxda5aZINFtjoEk4EAASPAQxW1GODC74Hhsor2fWPOaMdBmAE7QzZBspnQ6gtMv9YjBmpRTSKb0iBJGAP8cDrQTJFcUiLIcFst6IiyfGyFBDIZzA4cojj0LiMBkPrnFshmUZghd4A2IEJwROFQkKjTk/sRZSm5ltCMhgAFwuMkQa5LuAKnKIz3HadKTci4IREhCQ0QnHip5bIkX3VqJSHCCEYzgBCxFSVKDyhFmrSYBFZ1pSQ86oSAEwAZFKIINAhCEm4hOS8WKGuqYmhM3Zm1CN+CBETpoBB409KzuPNH93kZWikBOefNMSLswd7mcnLMtHOiBBwfQA3+mhKhGRWr0PIIAeH5Si6cbiSwfwp79vI8he7UcPhsUAiAMdoNAoONJrIpVrXJVcx5pzHCialGaYoQBSHRA8FC0rrv//UWFsjUAnBBgreXp8FWj2cFSEUKBKJTgswNYwgsG0IIn4uAD0NUB+DKS1rVysK1vDaJHCODK7mKroK4liAkgQN7ympe8LigIkgqipL80BksBOFkAogQs9D0GgA0gZk/+upUdcEC0BunAB3DQAsIe97MlECxyF2yBJ2YAuh+QrvgQEtjBFrZVcwvvQC4ggA57+MMdhoB6I+sugcIUWBZrmrjAE8a+GuwyN9DmDgbSAR1kwAKDBUQAhjDYIWwTABX4ngYgnIEn4njBSB7AExXh2c+GNoEccd93U4K2FEzgyljO8pVZUBDYFkRoyTpxqlIcrfeFx6wUsswNgKMBH2xg/7AWyIB0BQKDA3ewBDCYCPh0AGEcPLHAFrazB0uQXSPijcRj1XBFGiO77bQXk/AdM2c2s6EXAXAB+sXTYVaQhOAIgYMteG4HDtI5IBRhg0UAAhFDQoHvGRe5JQAw4R5gowAUoAE9Be9UMWKALkVMtn1RTbvalavc4kx5zHOxV8kCgiDkYAQwALBCWv2BDUhgq8EBQhs6QIGGnICjASACO5W64x7/WLsh2c7tftraXQtVLP4twQt6cAQkHO4gAiZwB4FAHI/ypAIWsIGgN4hnDJPkAfmdr64Pwt+sNHwn2VwuB4VgA3/X+MZw9oEGKjDHENzgBCdIwgiyixMNDoAMMf8wNapVXb03noTd26vrXR6uExjYYLBCQEIV4CznURsF4BvEQbe/3RdxL9adMpWszO1C85xwgMeDPcLNQ/0BbivF5BKowT9LM9u80VXReWm6wZDbgzh0mykreLOSz/7R0oDz6+4W21cq4IMWBODTg32BKpmiAwkMQAI6kAjhCqAAB0QJUiaZ7FzEHhO6Azq5Eh90V5WS9g+uYCJ2VAxBCPqQovnRP7CMe6v6RPrSkz4rjuegBDJQgxCo1YMv4EDLjdL3vwe+iB/ZjAUJcOuHfDLX74nP0m1KkxrUXfWsJ8gJePCCTw/BBhyYMVIogIMNWuDy1gMJnLSI6dA0JDwE+Y7/nXJ9dOLfpAYZ8PsGV6/1g4QgB33hAAyGS5QaqP8DGCEcNXXlkMbMNkyA8xrDZ34rgX7q93fJhxXUZ33jk38iQToNAAe+MmUIsRepokgREIC+YRwEKBMGCGo+0IBZYX8bhH9AMhLLlDelwxCBMRDnIn7gB3YdaBIUoAHpB4IimBUUkAEMKDcPCFWEZz4M8Wie4R6SQRkDOIMdUYPVh4Ne0QGA5gNsd4IisYJsA1UNAWx+8XmLJINKuIQa0IQb1AIh+BUU4ANj6HMdYU2swSq8x1o++IUSQXThNm4FwYQdZAE6gH1fAYUbJIVS5U4DgSULJ4cNUWqnNgCpRkQroANi/zgAesiHYIGGzKWG7cYRCNBdrkSBQGWID5EEAzcAJeAEOnBk1reHZAF0A5ABU3iJG6Ejq5V4nugQJFBuHuRjUBeJZoF17ad0HiEwO/M0CrA6iTaLCxECoUhwVaABrSgWqih0shgSOpJ0JGWMCYGMsDZ5u7h+vViMHzGNVGaNCrECW9Bkg/VkZVF5AwCNKKF/BDCNEwR34kgQNdCEPKBgHXRhZVF7gLcScAOLwgGHaziPA7ECPnCAG3AFr3ddbkUW6rgBktiO30gcAhmHHUh/AtFEoPYB2EdaWbVVdhgW/Hh7LOGOE3SS8mh+N+BvA0F3B4gD3SgQiHVUGMkVFKB2EP/5EoxXjcS3ZuNWg6bYAhwJFyQ4ACaokxlmfla1ThVwgxuUAZZoFu8Xf/O3gJCYg4uTlDalUn1xBKCmA81YFsvXfAPwfBzABCWYZjJjflzZFzzABBmAlWjhetbFQS/AA2Egl0gpEidJja5oSivQlv0kfWyRA5F3Z9oINiEBMcFRkSGSUfVoBEewBE9gVEYVABxQk2Vxd5+ldzahOCoUO9EoRCvwAY+3ARpQFwFAdiypmCCBGpIUj6O5ORq5fj4QkXLxdJ91BHkGVx8RAbqBkrNJJAb5kjFZF05wcx6Uc9ImE4qjSI05nPRBh0YnEEC5kbhZFxkwBMzXQRTXmq75EaH/GV/SORuIuHIxkAhOuYrHaRcUcGR6wAHyRm/2NnvOGRKwKZzeaB6gOFgloJwtAJaVUQF+l3UA0GzPFm1+FRLA2ZcpORu1CHUd5GNuEJWFoQE9KCPSGJDlGRvYiGDNWRg8uI5hCVwgAZCiuZ+zoQTJKIqJmRfvmZZD4U0RIEHc5ZcDSR8UUI7IhY6FQaB/156b9REnQhiB1KGioQEFdo8WZlgX6ncWoJfmFBLDOBBVqqKi0QFH1gIKWZcDgF2GQYnsiCBU6jaEh6SGoY4SYIIeaVoh6Z5qd5QQkm6n0QAVhKZ4sQIjOgCAOBAzqVh5UQEFJgGpWSAgsX/qgqUw+gHq/4cD2WkZGuB3LSClM8qXL4WjOVoZkfpBFioalLgBJWohWpkXfshcQmoZN7lWU7SWHrEA5CeRP6p2/VgefZAHPHAGhcqqTXU7iKaocaGnHPQBoXoYILCSwDEG5/ERCMcXh4KpmUoXFMCoT/molbEDMKBOfdGbTyE6AuMfroqna1F7Stapl2E4w0GYo/qbcHIanBhzc1EDgNYCpyoaFcAE2BYAMSAV/LWsvfqsbtEBspqr5rGpLTAFfUFy6YqChbgWwPp3whogJgeqteikyVoSxLiwHsGYmAZzAwFANRGtHJQB1DoaVrmqAJADb5qw20WevsoQKpQaCYEBabI3aPYS4v+6AZRKGkBHqAShBJppHyXxTuCaEH30Jf0Ks5KDRsoGE0qahgZCgpOqFSZ5kiyLsQ5RtDMEiwrwAMNjbCqkGtcCLL3FPM90QyQBsOsnsPVhchYwrFHxjxQ5tAiBtdWyInYaLT+yFzN0Jfj1QwYUThVBAiEwuAWxAk24pm5Lsk2YAV0Bt7HYsgtBt5wRmq1xS93aF3sbMCtyZtJ0ESDQaSVQAkDAAQ11hiGbuKOhimrrcIfal7IJuQqBtbyhRYYCKt6xhRhzL3XLYg8gRhYRAyUgoT3AA16gfjl5ICQoATlbFdbkoBHRMlwYegxXEUWbH4sxGYeEtwYASbr0GaTEt17/gmkzVLMKcQLmeF07ZgHkehkICm2ixbaoOxXPOVsp6hBVIlbBh4Re6LLAgbTg0he8ZLuacjufQU3tMrbju7QNQQSJ6EE2MAX0EW/zVm8jAAZPKRagyaEOwXt94zLo4X2iRxWr+VlFAJ6kEXHeKXADsLqNi5/lop8NQbstooFJqC3IVcLmYXM4hwRdQBaK06AwvBB3Cy00/BvZoRUM/Fk2kLKjoZtRp61h8Zw8VL+RKxyuSh4xGMJTYb6DZQTnNhsjbGEm7BUZHJ0fIhD5CyAnkVlfEkMeGxIZAATBy0HDy8SjwZl5t3cY7MKx6awHYWmCIb3llxFsPCn1RT5+U8gZ/xGjQuAEARC6o4uwsmGYCPaiX/HDwfm6VlsRiuwrh6y0htyuFhGjEjBqgnsDITobjLCQdil7PryhZrzJvodsuDU8jPI0uuI7rXElX7sqjsSxC0HKyzsb73kEzOd80IeuUQzLwOGYVFgRl9IABlDImZEY7sUZurwyexUx5HsQQKq8EkLKXQB/mDl/ZiE6rvugEaEksPUYe2VD7bHNBpDNZCYwYTYRQHp94Yxj4MwWO9mJF3EANiJmaCwv8VxfSELPQIMt7eXLEZHP8UsawuwWZvNFSYcrstwQusUqWkRpH6N5HEMpe8E7MXQlHk1DxCMRGAqJEU2y/DzMY1HRtrYsg//YAM+U0QwBO0/Tve1xTA6QGIEcQ7xBbGbLHqKcECvNivv8dzAd0x9BS8Poa6/qrjwRLhCR1BMy0XChf58EwBfrizuRGIKsECPKuEvdz1uNgn5skUsxoiwcIFodF/8ciChhxxixgxv01vWRz019ziqL0xMRoys8IRCtmn8N1hsR1wxS2Iatq+HIESvw0oQNpS19FqKTQlvrv4gNqxbhcQLxzX2ts5SNF4pjGn1hN/IC2H8pESOgSozdIK/NdFSqLPP1SXJL1RRhxIMw2hIS27INEg7TGIMEuAD92BXBTwGwXG072Sz9bkSaAMUiT7ftrxFRi8CBBz9rHr5tMEeslrn/1yVPs9YO6I8WIZjZ2iCbCqpCAmIdNtfT604CTdPTzdYQYd3AkQM3YJ/0gdUvAQLKPB7sLQDuPcgcwZjNPN+PSRGOHAD4rd/1wd8usQMxIMkEE+ADjlriqcGqjdsPQQF+AARSUAgYAuEtEWMBkMoAMAEmcAEyIAICbuECMAMQQAMX8AMT4AFZ+ZovrMmbrc7BfGR6/eAX7BIgQM7k4QEToAIuAAEzAOPsHQAB3mEiAAEuUOM3juAPAcQ8zpMjQQJvRR43kN3WKdkTQuIrsQPg1hcQEOUyfgEmcONQ/uQpPgEXcAHkFeVSTuVWjuPUvRHQeeCw2xEcwAEnsE6D7uAE/xHZTD3iQ64SKn4BWDAcjRBiNP4DXDY4Fp4QV1bnd47n5FXnV0Yw3Q1lHTGezpw4KVHowaFTCwGkUVvmjY55oz4QVqbkEIACHpYFauAIw/EFOzXrC4HkP3ABS+7ing4BoD4BcQ5iBAKaOy7e430S9t0X2b3dBmLmgpfpLDDsMrDmAT7lbj4BACC4JwADI0AEYh4Swk7sEGDsT57pGJ5amQztoaMSRq7HCEGCyz0hJmfWDuTk7D3jFzABlx4USL7iNMDky/5hzc7MVMzlJGHEJ64QK63eE+LWiQPjMu4CKnDl2wrvBjeRsdzjJcFRREDxsd4gGH8RHmACC+9hF446IP9P6h2RzliOEWtmyQPR7yWy8hTR8jLQ3jMvv0Pvcq0bxBBPEiBABA4+oiYrIT4fEUD/YSLw8u1tFS5g9QJO4K+o4SRfEige9Sqf1xPxAzRA9SqQAvNS9E7hAWvOgfHeEShatV+/ElYZ5PUh9gxh9rjeYTOQ9qNHHFPBAk2OAibQdkfPe/3K4S1BynhPH3qv6TTQ9zHuAgX/FSaA6zNw+Wp89LWRQ0mfEoo99oPNECzgAk3u95ZPFi4QYnyO+B4x96Bf3CbRvtG2s6Et0U2I96ef+gKAAjQg7mThAcZ+AYLn8L4V6BwhwfRZAkLw6me9vimgAr4P/D9wFiyA6yhw/cf/j3RbHvofgcITZwNPUNkuvegGMf3ubv1pYQJSzvlb11Su+/10PRI6vJxIgOIeau45ABBBQFCwMEBCBQAJE6ZQIULAQwEyTHhQWNHiRYwZNW7k2NHjR4UeaDyUQRGkxQAnPxII0NJlywYqZSpMOdMmhyEDdO4ccASGTaBBhQ4lmhDECCRHerwoweGQQYQJPZiQATHixKJZtRZN4VDABaE1tbJ86TLm1oxi0WIMwJNnjxFr5c6li3GEjbIvAUytClEE1rqBBU9AIQDFhKFqsxJg3Jix4ISK6wYQ4lbnixyQNW+eGQKJkABWIQbo+1CEihScVWtVYTp1YroHCgQocECz/2S6aV5YHlAiyGrgwSvCODIgtGgBx0+/Ft5cpciHNEzClnugrAHIuOX66MHDiNsXHEA4J695RA/jyJO7YF7e/UYWXlVo1U6UgYIHBB4oYJBd8IqCBjCEhxcqG8IGDnZ4b0G5ctjtONHqY/C9HwpDgYWtJBRKgQUUWkCBlTBoKQHsAHAggQAScIAjDYmqQQKDagAghBxa4gAGEibUsSgWsCghPeRaFIyB/na06ALTpstKSJsWCACDBkTs0CME8AOggZoSsO2ABFis6wOdLFjBSDJPAiGJjFJwYQYBrGjiBQitYhIjA2YLgAEEyiTKg75okGtOmQiwkzYCZHKgAAAeEP8rgAc2AlQlCjbQKQM9K+UIhBjiqoghrwxDZA8e4hzNpggCsA0ABhIo1NKZWGBTABPmelQlAg5o4IBVVVogzzoVKiACR+WqAEYJNGD1WIt2iCEATTm1SiIAcBgAjbxcskmBsxKqDYACGGipSANQJBGAD2crIM8FOiyXtjyrHPHU1UwobAYMZd3xgEYB6FVbYDWa1SMdwowKWWR34KClMkyA4FnAMoAqw34TSpfb/hAg8dA8I1D1w0YLiGlijrmNiciEFICXMxcegkDJtf796AAMIlaJgYgVTYilRkOotqWtKJB2ABwoIJhgg13SwgqVAUvI4QFkhLiiiQsoMV3rXkL/YGJy1dVa4g4DWBHVkyHzYGEBXBDMZY+wpA1fkKoMW0sAuPQyqwoC1GFoog9+qQ4+2ltaJ2PRwraibaVOCMoDQIR6SpC3zhoArxNiIOzAXDUs1rPpcmABOynPyIHrTBT3a3+z0oDYgfGu9Ac29C4rhvEqAnOAwNEq9dRUC932ARVBx26/xx9vnGsABn9gW81MMK3ezOlCQLYAsp2sKKY3EFp1PX+gobCHZmAPABJCED9HhTQAnK46v823ABRNTYjLlhwfHuuJj6cNecFGiojl6eWKwNuW/Mo/QgGQTj6AvTKxwAXcE4D3mKcR8w3ggKoxHFosRjq6eMArYOEM2jqC/6UEYACDgfEgAF4UIwTuSIGvMowLHriRCFJqNRUsigHMIhgWWOgHqynhRgyAK9V4cHZiSiGD1MRCFNBghyCJYRFV0xoBiOCFt3EiTWwSKZ34oIq32dlCGgKRJC7xJMMagAy3GBjoCEA6wekhg/7VAWLV7oyTUU8AvggRaM2EjDiYY2C68pD5CKeNC5pVwAZggdT1UVZ1xKPSZEJGC1xPkWshjGEQ05xBZsQxuSLhSXw2KUlOcpFBgoAj9QijSIpyLUiKot+Ak8mLqM0lCZhS/zxSgRbo5G6qpGOQiEKBXKaSl1nhU3TcA0uLyPIlnsvQR043gBYkcphZYcgMRPWQHv8S5JChDMy6FICuBVjHAOFK0e8UED99tQ87FZQaAhhVAESpzUpEic9DMFceZFakAQpgjKLCpTi6tIgC1ePmNIlCldHUUSjalMCYNvOhPHGIXArADsYAoDECYKBDD8AAAMZlgJiw0wDuXEChDlCkBhRJJTsLwIUIORcFKM6d+wSovTZSQAkaVCsKZGApr5mcoDBUmt2cUq+wVjWXPI+WuONQiUTqzjyh6iWIkslPA8A/5+RTISJiQEpNFdNOauSEEuiATvd0xwZe4DUsDYqkDrKao4Iorhd5wAIYUIBCGeBDHX1qAKLa1bAo1I1zsZhLzmWysGLEB2FyqFmBoj2r0OD/knIBgRceBteOEgCxWPNdokDEgIoyykqJK15MwjVSv74vAY3S60ysOiGtKqRWt+KkLSuCxQFo0bE2OaJfTIkWJXBgCQMoK3AW0L4iYS1u7esQUnElItqsCHQBUACJoOqhd7lWsC+li2OoaBE4GkSOu/3IVDqFgu/VhQQjaIkUxssZ5ZbpAq8drFzsd0O6gCAINYJBCBRiSESS9yQT2B4exViXILguCs2J744mwCb6cnctAMSvXAxWghf04AhIGMEffpaBggoYIym4AAtPg9W17IC9elHdCQSTgr6gIMLviS2qztUYupCAA7vZiRBs8CPaibgjCH1IEqdIlx0Q4XXY/6uxQlTAPRd4gK31XUsE8IrjucDABpYRAhLeMFQhJ4QFBSbJPVXziB4soSU/UV2TJ+AVCByZTDVWZvTmghPe+CTMF/EAWmegVuHEcFm/abNc0oiCQCKLzmWRXoZ4MwC47FkhPyhNEicbnApMCgA7CIB/C42WJ0cHxXpq8iYDWhnLYGaaU1YTA/8y6s2Q0YxoYvJWWEA2EVyaYKX27lwcxBvfrLqOJuiU91yJaVSGGG+Z9EDKDJPoT6+lzo3WSgi8Ax7xCDtIEFHigiCp7GUXhQrcK0kRF/0SamvlBAQyEIIUpO0InZhBFEj2GT0IAiXAgANQaKCuaz0XxwiQLjSyEf+OdDrj92hTmCkkwQ0ik5AbkM8jJNivS5oACQ5WkdcEQEC3BnhGEMTOIpxCeHkY2tgUgoADRDhBAE7AAQ58RAnLKoscjo3Ac7tEpbZ1IqZEDgBnYXO77hHqGZNQFlp75AZKdgkRfq7xuSizAPlKbM+X5cVOXaXkzinIW89IgrJIvCMXQIEgXOLwPm68tjxHYNHsmHWJmGTK7nGY1+dYo5ZkxiMPVtmyiDDJJlcEsc0rotshFHdkMQ3MRVSCSzy9ERgXeYctR3vaBcOSdLesiCmwg+sCsIjfVopp7z2jkv/OkVCXzSRJFmXgb2Znwg+NU1loQl7YnPjzqTIIAag8Rt7/rLIXPt7ya9kk5j9+LPNCBApcGEHzm7+spFsqgqSfIwicnpFDm3nV0q5W5tHi+q3wxSrLKeL0DSr8iqR+jY7Vap1hcnwjid8vqKliE0Vczyj626CxLf7abboj+TMN+tsi+yOvZisyaNst8OsgHQnAKBpABAoBGBiBHBCITCujVdsZcoO17duiBayIKXNA8iuio0iKpWgKJsBAeJOTfpO0D/yuzbAqIhPAm1Odu0C1y+ABQji4Osq4PXtB+DsbRqLBPvIMHNwJG7i9Ydo6EQPC2MuOOhpByBCfEBC7uiAO3hiCmFOkFJiACVCBC7gACGBCAXPCqkMLLwxDCCAbMpSL/xvgACAogRIIgCR4uqKggA7ogA/4gAx4AvTgjRecu1ZJwwtwgTXMuggZuh+0tz2ZgB8oRAhAxET0Jc0IAh74wwEYghKIgaCogA6ogT3cgA2AEctYAh5zC9CIQUW8CC+cgDA0RAhgIfUAozWkgTD8gTZUQI3rIsibABOAREkcPwhwgQv4gQlIjVzUCrD7DrcAAhfbCDzsAB3gQ1F8NJ4QxQz4AB2YAyADD72DwiDxwke8ABpYQwaaxe6pxVv0Qn9ZRSEzw1GKEIVgAV8kx1hERwFYw3UctWTMihPYMssogtPzRFD8AFHMJWuEJlHcwxrogKFSuVPUCSPgAfQjplZ0xP8wtCp8bKA1JMYL8EI56whBXEQnsioIOEfk0MeP1D8W4UXBGIEieLS2SMhD2oBs/IA8BLeMMBgbyAkheAEeeEaOuMgvDMMwlIE1XENZnEWrEgGVVAGQlDQeqpSq+aZ23LYigwAZuACoDMljgUmZ1AkJWMgP0ACHfA6iJEoqoIPaC4BAMAOjLMekDMaNnMWk7Mj5ckepfCU9UZRGwYCOSos6mgCvVKG0bEWjDEMuAEi3KAItWIO7jMy6nEzKxEenTEpbNEoTuMjChBy93Msg0pOTSogTuUp5FAwPcMXETExYjEylrEx0vIMAYEaeAAJ+g82NdE3dXMOtTEyijEc5AU3/8oBHXZkSd/I/z6TEysHNyZyB3RzG1RSDS9wJTYyBw7zIGtw1lxRONtITrDnOGamWOmIp8ixP8zxP9EzPl4jDOVRP93xP+IxP+ZxP+qxP+7zP+BTNItEYf9nOM1QNnanC7hSk4STQrMIevwQAwJwbvsQkBzXQB23QCMWbqoyq0hlQCJVQDcXQqTzQDtzQDuXQEM3Q0PTQJSTREU3REp3QFUVRwHNRBoRRGJTRJwTRFxVRFY1RHM3RGd1RRSJOyDFRG43BAvVRHeUloVyNJAWOJVWNJuWMJ3VS4YhSKOVOK71SLM1SLd1SLu1SL/1SMNWRE0mRERqSlyjTwBg8AHAX//cJjFIBQRaLDfxiU2baiv1oiXkqi7pwkpY4lTFVEcFwgHOirjyZrm/pI7iRG86YHOCwoTZV0I5KULqwExBEU7kArYuKnAWVVPTBgELhj8iwVMFhrQAolETtksCwFQDQrJgAHVGymcigOshg1OCgVY/6GludC1elCVENqDwBVLDZjAOYksgRVhCBVciR1broOGDZVUXaF26RGTPt09Wg1esiF+/LCmeFnADq1a04gBW51gXI1q3IKJro1sBwVNaiqmiFjNkITEO1yjOCVoFTDRtS1iE5FXElV6LYVg9BVTctkX3VDE+9iOOCjHAhAHqV1u5S01VVgMDcIljFGTby1v8JgxdgdVi58FfSBD9VVYiMrVOtqBILrQiOlRUHmFhGEdadi5uWdaJT5QySXS7kpAtb3dSVrQtnNYDAJJm6YICIPZxIzVnNWa2K4FnJeVmtcAA8oVmP2hKApQsMsI2Os41wWlONdaI/tdhyBaAC4FqtcNSWCNdBFdmiGJT+uFNCJaGX6BA6FQykagkEUFt5lQsE8Nqv2Vq4bZ/AJKcnCVPADVzBHVzCLVzDPVzETVzFXVzGbVzHfVzIjVzJnVzKrVzLvVzMzVzN3VzO7VzP/VzQDV3RHV0fuhPnwJJaIl3VrYhSmSWz5QwCSABVEQqyWBUUwdc1hS7YK5liXV3fLRX/EOm43nUO63jdjqjdhLjdixCUAAAW61CpUgla3yVd4OVdAygVWmreB/BaYMkol+io9GmJB8CSjrIOEDknzgGR8G3aivAWC42AQWUUEcGA2aCZ+rUI5PUoolUI66ilc4oY9pne36WuNZVdAmjdlrAyvFKULhGRbGHgXCHfuCHg+FUA0OmP57UI2VUI0DmXrbKz2Qip4SWLssiXx1DQR3USeBER3BVgz0Vg6gIW7E0IsXWJuvqWBuC4EWkA7JBg8y2eNuXTWaoIlgAo1K0IEbGNc1LiR13VlrDdleXTDkli7Frh/XVh0K1e1k0RGqaNWPLai2oAdfJhCg7iAEhdDQbY7yP+YCZuYyJ+4uRd2QN4nubtX4X43w9uYSzeXC1WiBleVRShWgbIFRtiV24JgHHyYiw53zbF3kaJAOl134714MNxnyUG4pPJX+V9H0ZhXuclYF+J2j3+3D5OiD9OFArrqPhlgAeAYdsgAG8pABFhZHgxgPgNm+JVCFu2YSq+5EuWLTjW33zhHePU3dSN3lFO5uaI3dn1H1qq2TseXmWe5s2wIaUlChLeXYxYY2ruZifqNW8OZ3EeZ3IuZ3M+Z3ROZ3VeZ3ZuZ3d+Z3iOZ3meZ3quZ3u+Z3zOZ33eZ37uZ3/+Z4AOaIEeaIIuaINm3IAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure-volume relationships for the inflation and deflation of surfactant-deficient and surfactant-treated preterm rabbit lungs. The control lungs are from 27-day preterm rabbits. Rabbits with surfactant deficiency have high opening pressure, low maximal volume at a distending pressure of 35 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, and the lack of deflation stability at low pressures on deflation (orange squares). In contrast, treatment of 27-day preterm rabbits with a natural surfactant alters the pressure-volume relationships with lower opening pressure, improved maximal volume at a distending pressure of 35 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, and deflation stability at low deflating pressures (green circles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Jobe AH. Lung development and maturation. In: Fanaroff &amp; Martin's Neonatal-Perinatal Medicine - Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier, St. Louis 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43102=[""].join("\n");
var outline_f42_5_43102=null;
var title_f42_5_43103="PedNIHSS items";
var content_f42_5_43103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric National Institutes of Health Stroke Scale (PedNIHSS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        PedNIHSS INSTRUCTIONS: Administer stroke scale items in the order listed. Follow directions provided for each exam item. Scores should reflect what the patient does, not what the clinician thinks the patient can do.",
"        <em>",
"         <strong>",
"          MODIFICATIONS FOR CHILDREN: Modifications to testing instructions from the adult version for use in children are shown in bold italic with each item where appropriate. Items with no modifications should be administered and scored with children in the same manner as for adults.",
"         </strong>",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Item# and instructions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scale definition and scoring guide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1a. Level of consciousness:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The investigator must choose a response, even if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Alert; keenly responsive.",
"        </p>",
"        <p>",
"         1 = Not alert, but arousable by minor stimulation to obey, answer, or respond.",
"        </p>",
"        <p>",
"         2 = Not alert, requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped).",
"        </p>",
"        <p>",
"         3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, areflexic.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1b. LOC questions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The patient is asked the month and his/her age. The answer must be correct - there is no partial credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded and that the examiner not \"help\" the patient with verbal or non-verbal cues.",
"        <em>",
"         <strong>",
"          Modified for children, age 2 years and up. A familiar Family Member must be present for this item: Ask the child \"how old are you?\" Or \"How many years old are you?\" for question number one. Give credit if the child states the correct age, or shows the correct number of fingers for his/her age. For the second question, ask the child \"where is XX?\", XX referring to the name of the parent or other familiar family member present. Use the name for that person which the child typically uses, eg, \"mommy\". Give credit if the child correctly points to or gazes purposefully in the direction of the family member.",
"         </strong>",
"        </em>",
"       </td>",
"       <td>",
"        <p>",
"         0 = Answers both questions correctly.",
"        </p>",
"        <p>",
"         1 = Answers one question correctly.",
"        </p>",
"        <p>",
"         2 = Answers neither question correctly.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1c. LOC commands:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The patient is asked to open and close the eyes and then to grip and release the non-paretic hand.",
"        <em>",
"         <strong>",
"          For children one may substitute the command to grip the hand with the command \"show me your nose\" or \"touch your nose\".",
"         </strong>",
"        </em>",
"        Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to them (pantomime) and score the result (ie, follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Performs both tasks correctly.",
"        </p>",
"        <p>",
"         1 = Performs one task correctly.",
"        </p>",
"        <p>",
"         2 = Performs neither task correctly.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        2. Best gaze:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI) score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre-existing blindness or other disorder of visual acuity or fields should be tested with reflexive movements and a choice made by the investigator. Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal.",
"        </p>",
"        <p>",
"         1 = Partial gaze palsy. This score is given when gaze is abnormal in one or both eyes, but where forced deviation or total gaze paresis are not present.",
"        </p>",
"        <p>",
"         2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        3. Visual:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting",
"        <em>",
"         <strong>",
"          (for children &gt;6 years)",
"         </strong>",
"        </em>",
"        or visual threat",
"        <em>",
"         <strong>",
"          (for children age 2 to 6 years)",
"         </strong>",
"        </em>",
"        as appropriate. Patient must be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear-cut asymmetry, including quadrantanopia is found. If patient is blind from any cause score 3. Double simultaneous stimulation is performed at this point. If there is extinction patient receives a 1 and the results are used to answer question 11.",
"       </td>",
"       <td>",
"        <p>",
"         0 = No visual loss.",
"        </p>",
"        <p>",
"         1 = Partial hemianopia.",
"        </p>",
"        <p>",
"         2 = Complete hemianopia.",
"        </p>",
"        <p>",
"         3 = Bilateral hemianopia (blind including cortical blindness).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        4. Facial palsy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ask, or use pantomime to encourage the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barrier obscures the face, these should be removed to the extent possible.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal symmetrical movement.",
"        </p>",
"        <p>",
"         1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling).",
"        </p>",
"        <p>",
"         2 = Partial paralysis (total or near total paralysis of lower face).",
"        </p>",
"        <p>",
"         3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        5 &amp; 6. Motor arm and leg:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine) and the leg 30 degrees (always tested supine). Drift is scored if the arm falls before 10 seconds or the leg before 5 seconds.",
"        <em>",
"         <strong>",
"          For children too immature to follow precise directions or uncooperative for any reason, power in each limb should be graded by observation of spontaneous or elicited movement according to the same grading scheme, excluding the time limits.",
"         </strong>",
"        </em>",
"        The aphasic patient is encouraged using urgency in the voice and pantomime but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder or hip,",
"        <em>",
"         <strong>",
"          or immobilization by an IV board,",
"         </strong>",
"        </em>",
"        may the score be \"9\" and the examiner must clearly write the explanation for scoring as a \"9\". Score each limb separately.",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          5a. Left arm",
"         </strong>",
"         <br/>",
"         <strong>",
"          5b. Right arm",
"         </strong>",
"        </p>",
"        <p>",
"         0 = No drift, limb holds 90 (or 45) degrees for full 10 seconds.",
"        </p>",
"        <p>",
"         1 = Drift, limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support.",
"        </p>",
"        <p>",
"         2 = Some effort against gravity, limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity.",
"        </p>",
"        <p>",
"         3 = No effort against gravity, limb falls.",
"        </p>",
"        <p>",
"         4 = No movement.",
"        </p>",
"        <p>",
"         9 = Amputation, joint fusion explain.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          6a. Left leg",
"         </strong>",
"         <br/>",
"         <strong>",
"          6b. Right leg",
"         </strong>",
"        </p>",
"        <p>",
"         0 = No drift, leg holds 30 degrees position for full 5 seconds.",
"        </p>",
"        <p>",
"         1 = Drift, leg falls by the end of the 5 second period but does not hit bed.",
"        </p>",
"        <p>",
"         2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity.",
"        </p>",
"        <p>",
"         3 = No effort against gravity, leg falls to bed immediately.",
"        </p>",
"        <p>",
"         4 = No movement.",
"        </p>",
"        <p>",
"         9 = Amputation, joint fusion explain.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        7. Limb ataxia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, insure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness.",
"        <em>",
"         <strong>",
"          In children, substitute this task with reaching for a toy for the upper extremity, and kicking a toy or the examiner's hand, in children too young (&lt;5 years) or otherwise uncooperative for the standard exam item.",
"         </strong>",
"        </em>",
"        Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion may the item be scored \"9\", and the examiner must clearly write the explanation for not scoring. In case of blindness test by touching nose from extended arm position.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Absent.",
"        </p>",
"        <p>",
"         1 = Present in one limb.",
"        </p>",
"        <p>",
"         2 = Present in two limbs.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        8. Sensory:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sensation or grimace to pin prick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient.",
"        <em>",
"         <strong>",
"          For children too young or otherwise uncooperative for reporting gradations of sensory loss, observe for any behavioral response to pin prick, and score it according to the same scoring scheme as a \"normal\" response, \"mildly diminished\" or \"severely diminished\" response.",
"         </strong>",
"        </em>",
"        Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas [arms (not hands), legs, trunk, face] as needed to accurately check for hemisensory loss. A score of 2, \"severe or total,\" should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will therefore probably score 1 or 0.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal; no sensory loss.",
"        </p>",
"        <p>",
"         1 = Mild to moderate sensory loss; patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick but patient is aware he/she is being touched.",
"        </p>",
"        <p>",
"         2 = Severe to total sensory loss; patient is not aware of being touched in the face, arm, and leg.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        9. Best language:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A great deal of information about comprehension will be obtained during the preceding sections of the examination.",
"        <em>",
"         <strong>",
"          For children age 6 years and up with normal language development before onset of stroke: The patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet, to repeat words from the attached list, and to read from the attached list of sentences (see Table S1&nbsp;\"Language testing items\"&nbsp;below, and see&nbsp;separate figures for&nbsp;Cookie theft picture, Picture naming for PedNIHSS, and Reading&nbsp;for PedNIHSS).",
"         </strong>",
"        </em>",
"        Comprehension is judged from responses here as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in coma (question 1a = 3) will arbitrarily score 3 on this item. The examiner must choose a score in the patient with stupor or limited cooperation but a score of 3 should be used only if the patient is mute and follows no one step commands.",
"        <em>",
"         <strong>",
"          For children age 2 yrs to 6 yrs (or older children with premorbid language skills &lt;6 yr level), score this item based on observations of language comprehension and speech during the examination.",
"         </strong>",
"        </em>",
"        The patient with brain stem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic score 2. Patients in coma (item 1a = 3) are arbitrarily given a 2 on this item.",
"       </td>",
"       <td>",
"        <p>",
"         0 = No aphasia, normal.",
"        </p>",
"        <p>",
"         1 = Mild to moderate aphasia; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conversation about provided material difficult or impossible. For example in conversation about provided materials examiner can identify picture or naming card from patient's response.",
"        </p>",
"        <p>",
"         2 = Severe aphasia; all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response.",
"        </p>",
"        <p>",
"         3 = Mute, global aphasia; no usable speech or auditory comprehension.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        10. Dysarthria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If patient is thought to be normal an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if the patient is intubated or has other physical barrier to producing speech, may the item be scored \"9\", and the examiner must clearly write an explanation for not scoring. Do not tell the patient why he/she is being tested.",
"       </td>",
"       <td>",
"        <p>",
"         0 = Normal.",
"        </p>",
"        <p>",
"         1 = Mild to moderate; patient slurs at least some words and, at worst, can be understood with some difficulty.",
"        </p>",
"        <p>",
"         2 = Severe; patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric.",
"        </p>",
"        <p>",
"         9 = Intubated or other physical barrier, explain.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        11. Extinction and inattention (formerly neglect):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosognosia may also be taken as evidence of abnormality. Since the abnormality is scored only if present, the item is never untestable.",
"       </td>",
"       <td>",
"        <p>",
"         0 = No abnormality.",
"        </p>",
"        <p>",
"         1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities.",
"        </p>",
"        <p>",
"         2 = Profound hemi-inattention or hemi-inattention to more than one modality. Does not recognize own hand or orients to only one side of space.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Table S1. Language testing items for PedNIHSS:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Repetition",
"       </td>",
"       <td>",
"        Each of 4 word-repetition tasks is presented:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         a. Stop",
"        </p>",
"        <p>",
"         b. Stop and go",
"        </p>",
"        <p>",
"         c. If it rains we play inside",
"        </p>",
"        <p>",
"         d. The President lives in Washington",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reading",
"       </td>",
"       <td>",
"        Each of 3 items is presented for the child to read (see separate&nbsp;\"Reading items figure&nbsp;for PedNIHSS\"). Adjust expectations according to child's age/school level.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Name",
"       </td>",
"       <td>",
"        Pictures are presented of a clock, pencil, skateboard, shirt, baseball, and bicycle (see separate&nbsp;\"Picture naming figure for PedNIHSS\").",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluency and word finding",
"       </td>",
"       <td>",
"        The Cookie theft picture&nbsp;is presented and the child is asked to describe what he/she sees (see separate&nbsp;\"Cookie theft picture for NIHSS and PedNIHSS\").",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_5_43103=[""].join("\n");
var outline_f42_5_43103=null;
